TY  - JOUR
AU  - Antanasković, Ana
AU  - Stević, Ivana
AU  - Gojak, Refet
AU  - Lakić, Dragana
AU  - Janković, Slobodan
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5269
AB  - Alpha-mannosidosis is an inherited rare disorder of mannose-containing oligosaccharides metabolism that is currently treated by enzyme replacement therapy (ERT), bone marrow transplantation (BMT), or supportive therapy (ST). However, the relative cost-effectiveness of these treatment options is yet unknown. Our study aimed to compare the cost-effectiveness of the treatment options for mild to moderate alpha-mannosidosis. The study is based on a modeling approach using a Discrete-Event Simulation model to generate and simulate the course of the disease under the influence of each of the treatment options: ERT, BMT, and ST. The model had a lifetime horizon and was made from the perspective of the Serbian Health Insurance Fund. Currently, available causal therapy of mild to moderate alpha-mannosidosis with velmanase alpha enzyme replacement is not cost-effective compared with supportive therapy (ICER = 941,587,152 RSD) or bone marrow transplantation (ICER = −398,412,755 RSD). Bone marrow transplantation can be cost-effective compared to supportive therapy (ICER = 6,032,689 RSD), but only if the willingness-to-pay threshold is increased to 9 gross domestic products (GDP) per capita per QALY gained. According to the current threshold, velmanase-alfa is not cost-effective compared to BMT or ST. To make alfa-mannosidosis therapy widely accessible to patients, criteria for assessing the cost-effectiveness of orphan drugs must include not only the absolute value of ICER but other aspects like equity weightings of QALYs, risk-sharing, reimbursement of severe forms of a disease only, or availability of dedicated funding.
PB  - Taylor and Francis Ltd.
T2  - Biotechnology and Biotechnological Equipment
T1  - Cost-effectiveness of velmanase alfa vs. bone marrow transplantation or no causal therapy in patients with mild to moderate alpha-mannosidosis
VL  - 37
IS  - 1
DO  - 10.1080/13102818.2023.2271574
ER  - 

@article{
author = "Antanasković, Ana and Stević, Ivana and Gojak, Refet and Lakić, Dragana and Janković, Slobodan",
year = "2023",
abstract = "Alpha-mannosidosis is an inherited rare disorder of mannose-containing oligosaccharides metabolism that is currently treated by enzyme replacement therapy (ERT), bone marrow transplantation (BMT), or supportive therapy (ST). However, the relative cost-effectiveness of these treatment options is yet unknown. Our study aimed to compare the cost-effectiveness of the treatment options for mild to moderate alpha-mannosidosis. The study is based on a modeling approach using a Discrete-Event Simulation model to generate and simulate the course of the disease under the influence of each of the treatment options: ERT, BMT, and ST. The model had a lifetime horizon and was made from the perspective of the Serbian Health Insurance Fund. Currently, available causal therapy of mild to moderate alpha-mannosidosis with velmanase alpha enzyme replacement is not cost-effective compared with supportive therapy (ICER = 941,587,152 RSD) or bone marrow transplantation (ICER = −398,412,755 RSD). Bone marrow transplantation can be cost-effective compared to supportive therapy (ICER = 6,032,689 RSD), but only if the willingness-to-pay threshold is increased to 9 gross domestic products (GDP) per capita per QALY gained. According to the current threshold, velmanase-alfa is not cost-effective compared to BMT or ST. To make alfa-mannosidosis therapy widely accessible to patients, criteria for assessing the cost-effectiveness of orphan drugs must include not only the absolute value of ICER but other aspects like equity weightings of QALYs, risk-sharing, reimbursement of severe forms of a disease only, or availability of dedicated funding.",
publisher = "Taylor and Francis Ltd.",
journal = "Biotechnology and Biotechnological Equipment",
title = "Cost-effectiveness of velmanase alfa vs. bone marrow transplantation or no causal therapy in patients with mild to moderate alpha-mannosidosis",
volume = "37",
number = "1",
doi = "10.1080/13102818.2023.2271574"
}

Antanasković, A., Stević, I., Gojak, R., Lakić, D.,& Janković, S.. (2023). Cost-effectiveness of velmanase alfa vs. bone marrow transplantation or no causal therapy in patients with mild to moderate alpha-mannosidosis. in Biotechnology and Biotechnological Equipment
Taylor and Francis Ltd.., 37(1).
https://doi.org/10.1080/13102818.2023.2271574

Antanasković A, Stević I, Gojak R, Lakić D, Janković S. Cost-effectiveness of velmanase alfa vs. bone marrow transplantation or no causal therapy in patients with mild to moderate alpha-mannosidosis. in Biotechnology and Biotechnological Equipment. 2023;37(1).
doi:10.1080/13102818.2023.2271574 .

Antanasković, Ana, Stević, Ivana, Gojak, Refet, Lakić, Dragana, Janković, Slobodan, "Cost-effectiveness of velmanase alfa vs. bone marrow transplantation or no causal therapy in patients with mild to moderate alpha-mannosidosis" in Biotechnology and Biotechnological Equipment, 37, no. 1 (2023),
https://doi.org/10.1080/13102818.2023.2271574 . .

TY  - JOUR
AU  - Tadić, Ivana
AU  - Trajković, Marija
AU  - Tešić, Ivana
AU  - Lakić, Dragana
AU  - Stević, Ivana
AU  - Šesto, Sofija
AU  - Odalović, Marina
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4239
AB  - Stress is one of the most significant factors that can influence the academic
performance of students. To explore the causes of stress in students, the crosssectional
online survey was conducted during semester (in 2019 year) and during
examination period (in 2020 year) period at the University of Belgrade - Faculty of
Pharmacy. The main results indicated that female gender was the most significant
predictor of stress during the examimation period, and the most frequent stress
sources were limited time to prepare exams and/or colloquia. The role of family,
friends, and boyfriend/girlfriend showed to be of great importance in stress reduction
during the semester and especially during the examimation period. The most frequent
manifestations of stress were feeling nervous, tired and worried. For stress reduction
students usually listened to music and talked with friends. Therefore, student’s
obligations and their overall living conditions should be observed comprehensively.
These results may indicate further actions to decrease stress levels in students, and
need for academic environment that may help students to achieve the best academic
performance.
AB  - Stres je jedan od najznačajnijih faktora koji mogu da utiču na akademske performanse studenata.
U cilju ispitivanja uzroka stresa u populaciji studenata Farmaceutskog fakulteta Univerziteta u
Beogradu, sprovedena je studija preseka tokom semestra (u 2019. godini) i ispitnog roka (u
2020. godini), putem onlajn upitnika. Rezultati studije pokazali su da je ženski pol značajni
prediktor stresa tokom ispitnog roka, dok je ograničeno vreme za pripremu ispita/kolokvijuma
najznačajniji uzrok stresa. Porodica, prijatelji i partneri su najznačajniji u smanjenju stresa,
posebno tokom ispitnih rokova. Najčešće manifestacije stresa su osećaj nervoze, umora i
zabrinutosti. U cilju smanjenja stresa studenti sluščaju muziku ili razgovaraju sa prijateljima.
Time obaveze i uslove života studenata treba sveobuhvatno posmatrati. Rezultati ove studije
mogu ukazati na dalje mere i aktivnosti kako bi se umanjio stres kod studenata, kao i na to kakvo
akademsko okruženje treba razviti da bi se poboljšale akademske performanse studenata.
PB  - Faculty of Medical Sciences University of Kragujevac
T2  - Serbian Journal of Experimental and Clinical Research
T1  - Assessment of causes of stress in a pharmacy student population during semester and examination period
T1  - Analiza uzroka stresa u populaciji studenata farmacije tokom semestra i ispitnog roka
DO  - 10.2478/sjecr-2022-0030
ER  - 

@article{
author = "Tadić, Ivana and Trajković, Marija and Tešić, Ivana and Lakić, Dragana and Stević, Ivana and Šesto, Sofija and Odalović, Marina",
year = "2023",
abstract = "Stress is one of the most significant factors that can influence the academic
performance of students. To explore the causes of stress in students, the crosssectional
online survey was conducted during semester (in 2019 year) and during
examination period (in 2020 year) period at the University of Belgrade - Faculty of
Pharmacy. The main results indicated that female gender was the most significant
predictor of stress during the examimation period, and the most frequent stress
sources were limited time to prepare exams and/or colloquia. The role of family,
friends, and boyfriend/girlfriend showed to be of great importance in stress reduction
during the semester and especially during the examimation period. The most frequent
manifestations of stress were feeling nervous, tired and worried. For stress reduction
students usually listened to music and talked with friends. Therefore, student’s
obligations and their overall living conditions should be observed comprehensively.
These results may indicate further actions to decrease stress levels in students, and
need for academic environment that may help students to achieve the best academic
performance., Stres je jedan od najznačajnijih faktora koji mogu da utiču na akademske performanse studenata.
U cilju ispitivanja uzroka stresa u populaciji studenata Farmaceutskog fakulteta Univerziteta u
Beogradu, sprovedena je studija preseka tokom semestra (u 2019. godini) i ispitnog roka (u
2020. godini), putem onlajn upitnika. Rezultati studije pokazali su da je ženski pol značajni
prediktor stresa tokom ispitnog roka, dok je ograničeno vreme za pripremu ispita/kolokvijuma
najznačajniji uzrok stresa. Porodica, prijatelji i partneri su najznačajniji u smanjenju stresa,
posebno tokom ispitnih rokova. Najčešće manifestacije stresa su osećaj nervoze, umora i
zabrinutosti. U cilju smanjenja stresa studenti sluščaju muziku ili razgovaraju sa prijateljima.
Time obaveze i uslove života studenata treba sveobuhvatno posmatrati. Rezultati ove studije
mogu ukazati na dalje mere i aktivnosti kako bi se umanjio stres kod studenata, kao i na to kakvo
akademsko okruženje treba razviti da bi se poboljšale akademske performanse studenata.",
publisher = "Faculty of Medical Sciences University of Kragujevac",
journal = "Serbian Journal of Experimental and Clinical Research",
title = "Assessment of causes of stress in a pharmacy student population during semester and examination period, Analiza uzroka stresa u populaciji studenata farmacije tokom semestra i ispitnog roka",
doi = "10.2478/sjecr-2022-0030"
}

Tadić, I., Trajković, M., Tešić, I., Lakić, D., Stević, I., Šesto, S.,& Odalović, M.. (2023). Assessment of causes of stress in a pharmacy student population during semester and examination period. in Serbian Journal of Experimental and Clinical Research
Faculty of Medical Sciences University of Kragujevac..
https://doi.org/10.2478/sjecr-2022-0030

Tadić I, Trajković M, Tešić I, Lakić D, Stević I, Šesto S, Odalović M. Assessment of causes of stress in a pharmacy student population during semester and examination period. in Serbian Journal of Experimental and Clinical Research. 2023;.
doi:10.2478/sjecr-2022-0030 .

Tadić, Ivana, Trajković, Marija, Tešić, Ivana, Lakić, Dragana, Stević, Ivana, Šesto, Sofija, Odalović, Marina, "Assessment of causes of stress in a pharmacy student population during semester and examination period" in Serbian Journal of Experimental and Clinical Research (2023),
https://doi.org/10.2478/sjecr-2022-0030 . .

TY  - JOUR
AU  - Doneva, Miglena
AU  - Milushewa, Petya
AU  - Dimitrova, Maria
AU  - Kamusheva,  Maria
AU  - Stoitchkov, Jordan
AU  - Petrova, Guenka
AU  - Naydenova, Kremena
AU  - Krusheva, Borislava
AU  - Dimitrov, Vasil
AU  - Lakić, Dragana
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4202
AB  - This study aims to evaluate clinical characteristics, quality of life and control of treatment and therapy satisfaction of patients with asthma in Bulgaria. A pilot study of Bulgarian patients with asthma selected by allergologists was performed. The predefined inclusion criteria were asthma diagnosis with at least 6 months of living with asthma and use of asthma medication. Patient characteristics, treatment, quality-of-life, control of asthma and therapy satisfaction were systematically assessed. A retrospective observational study was conducted among asthma patients in Sofia in 2019. A strict definition of asthma-based solely on physicians’ diagnosis was used. Allergologists from two national reference hospitals for asthma therapy selected asthma patients. Every third patient with asthma that visited the office within 5 months period, and that agreed to participate was selected for the study. Quality-of-life of patients was measured using the EQ5D Assessment Test, control of asthma was assessed using ATCQ and ATC tests. A total of 71 asthma patients were enrolled. Approximately 43.6% were male, 16.9% were smokers, occupational risk factors were low (4.22%), 25% had moderate and 38% had severe asthma. The mean scores of asthma control treatment were 16.92 ± 5.68. The group has relatively high percentages of severe asthma patients. The asthma was not well controlled. National asthma strategies should focus on prevention and early detection of the disease.
PB  - Taylor and Francis Ltd.
T2  - Biotechnology and Biotechnological Equipment
T1  - Quality of life, control of treatment and satisfaction of patients with asthma in Bulgaria: a pilot study
VL  - 36
IS  - 1
SP  - 478
EP  - 485
DO  - 10.1080/13102818.2022.2098818
ER  - 

@article{
author = "Doneva, Miglena and Milushewa, Petya and Dimitrova, Maria and Kamusheva,  Maria and Stoitchkov, Jordan and Petrova, Guenka and Naydenova, Kremena and Krusheva, Borislava and Dimitrov, Vasil and Lakić, Dragana",
year = "2022",
abstract = "This study aims to evaluate clinical characteristics, quality of life and control of treatment and therapy satisfaction of patients with asthma in Bulgaria. A pilot study of Bulgarian patients with asthma selected by allergologists was performed. The predefined inclusion criteria were asthma diagnosis with at least 6 months of living with asthma and use of asthma medication. Patient characteristics, treatment, quality-of-life, control of asthma and therapy satisfaction were systematically assessed. A retrospective observational study was conducted among asthma patients in Sofia in 2019. A strict definition of asthma-based solely on physicians’ diagnosis was used. Allergologists from two national reference hospitals for asthma therapy selected asthma patients. Every third patient with asthma that visited the office within 5 months period, and that agreed to participate was selected for the study. Quality-of-life of patients was measured using the EQ5D Assessment Test, control of asthma was assessed using ATCQ and ATC tests. A total of 71 asthma patients were enrolled. Approximately 43.6% were male, 16.9% were smokers, occupational risk factors were low (4.22%), 25% had moderate and 38% had severe asthma. The mean scores of asthma control treatment were 16.92 ± 5.68. The group has relatively high percentages of severe asthma patients. The asthma was not well controlled. National asthma strategies should focus on prevention and early detection of the disease.",
publisher = "Taylor and Francis Ltd.",
journal = "Biotechnology and Biotechnological Equipment",
title = "Quality of life, control of treatment and satisfaction of patients with asthma in Bulgaria: a pilot study",
volume = "36",
number = "1",
pages = "478-485",
doi = "10.1080/13102818.2022.2098818"
}

Doneva, M., Milushewa, P., Dimitrova, M., Kamusheva, M., Stoitchkov, J., Petrova, G., Naydenova, K., Krusheva, B., Dimitrov, V.,& Lakić, D.. (2022). Quality of life, control of treatment and satisfaction of patients with asthma in Bulgaria: a pilot study. in Biotechnology and Biotechnological Equipment
Taylor and Francis Ltd.., 36(1), 478-485.
https://doi.org/10.1080/13102818.2022.2098818

Doneva M, Milushewa P, Dimitrova M, Kamusheva M, Stoitchkov J, Petrova G, Naydenova K, Krusheva B, Dimitrov V, Lakić D. Quality of life, control of treatment and satisfaction of patients with asthma in Bulgaria: a pilot study. in Biotechnology and Biotechnological Equipment. 2022;36(1):478-485.
doi:10.1080/13102818.2022.2098818 .

Doneva, Miglena, Milushewa, Petya, Dimitrova, Maria, Kamusheva,  Maria, Stoitchkov, Jordan, Petrova, Guenka, Naydenova, Kremena, Krusheva, Borislava, Dimitrov, Vasil, Lakić, Dragana, "Quality of life, control of treatment and satisfaction of patients with asthma in Bulgaria: a pilot study" in Biotechnology and Biotechnological Equipment, 36, no. 1 (2022):478-485,
https://doi.org/10.1080/13102818.2022.2098818 . .

TY  - JOUR
AU  - Lakić, Dragana
AU  - Stević, Ivana
AU  - Odalović, Marina
AU  - Tadić, Ivana
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3961
AB  - Economic evaluation in health (also known as pharmacoeconomic in case of medicines)
identifies, measures, and values costs and outcomes of alternative healthcare technologies, and
can be performed alongside controlled clinical trials, but analytical modelling is usually used.
Decision trees and Markov models are the two most common approaches used in economic
evaluation. The biggest advantages of a decision tree are clarity, simplicity, and
straightforwardness. On the other hand, the main advantage of the Markov model is its ability to
incorporate complex events into the simulation, which is practically impossible to do with a
decision tree. Reimbursement policy in Serbia mandatorily incorporates economic evaluations to
promote availability and accessibility of the prescription medicines. To show current
pharmacoeconomic value of a medicine, budget impact analysis and the cost-effectiveness
analysis should be included. The latter should be conducted using appropriate modelling
techniques. However, since no official methodological guidelines about the modelling and
economic analysis exist, the submissions by marketing authorization holders vary greatly. The
future of pharmacoeconomic modelling depends on the research area of interest, with new
frameworks and approaches being developed.
AB  - Ekonomske evaluacije u zdravstvu (ili farmakoekonomija u slučaju lekova) identifikuju, vrednuju i mere troškove i ishode alternativnih zdravstvenih tehnologija, i mogu se sprovoditi paralelno sa kliničkim studijama, ali se češće primenjuje modelovanje. Drvo odlučivanja i Markovljev model su dva najčešće korišćena modela u ekonomskim evaluacijama. Najveća prednost primene drveta odlučivanja je njegova jednostavnost, jasnoća i direktnost. Sa druge strane, najveća prednost Markovljevog modela je sposobnost da uključi kompleksne događaje u simulaciju, što je praktično nemoguće sa drvetom odlučivanja. Ekonomske evaluacije su obavezan zahtev u nekoliko procesa u cilju povećanja dostupnosti lekova u Srbiji. Kako bi se pokazala sadašnja farmakoekonomska prednost leka neophodno je sprovesti analizu uticaja na budžet i analizu troškovne isplativosti. Drugu analizu je neophodno sprovesti primenom odgovarajuće tehnike modelovanja. Međutim, kako ne postoje zvanične smernice o modelovanju i ekonomskim evaluacija, dokumentacija podneta od strane nosioca dozvole pokazuje značajno variranje. Budućnost modelovanja u farmakoekonomiji zavisi od istraživačkog interesa, pri čemu se razvijaju novi okviri i pristupi.
PB  - Beograd : Savez farmaceutskih udruženja Srbije
T2  - Arhiv za farmaciju
T1  - Modelling in economic evaluations of medicines
T1  - Modelovanje u farmakoekonomskim evaluacijama lekova
VL  - 71
IS  - 4
SP  - 354
EP  - 364
DO  - 10.5937/arhfarm71-32404
ER  - 

@article{
author = "Lakić, Dragana and Stević, Ivana and Odalović, Marina and Tadić, Ivana",
year = "2021",
abstract = "Economic evaluation in health (also known as pharmacoeconomic in case of medicines)
identifies, measures, and values costs and outcomes of alternative healthcare technologies, and
can be performed alongside controlled clinical trials, but analytical modelling is usually used.
Decision trees and Markov models are the two most common approaches used in economic
evaluation. The biggest advantages of a decision tree are clarity, simplicity, and
straightforwardness. On the other hand, the main advantage of the Markov model is its ability to
incorporate complex events into the simulation, which is practically impossible to do with a
decision tree. Reimbursement policy in Serbia mandatorily incorporates economic evaluations to
promote availability and accessibility of the prescription medicines. To show current
pharmacoeconomic value of a medicine, budget impact analysis and the cost-effectiveness
analysis should be included. The latter should be conducted using appropriate modelling
techniques. However, since no official methodological guidelines about the modelling and
economic analysis exist, the submissions by marketing authorization holders vary greatly. The
future of pharmacoeconomic modelling depends on the research area of interest, with new
frameworks and approaches being developed., Ekonomske evaluacije u zdravstvu (ili farmakoekonomija u slučaju lekova) identifikuju, vrednuju i mere troškove i ishode alternativnih zdravstvenih tehnologija, i mogu se sprovoditi paralelno sa kliničkim studijama, ali se češće primenjuje modelovanje. Drvo odlučivanja i Markovljev model su dva najčešće korišćena modela u ekonomskim evaluacijama. Najveća prednost primene drveta odlučivanja je njegova jednostavnost, jasnoća i direktnost. Sa druge strane, najveća prednost Markovljevog modela je sposobnost da uključi kompleksne događaje u simulaciju, što je praktično nemoguće sa drvetom odlučivanja. Ekonomske evaluacije su obavezan zahtev u nekoliko procesa u cilju povećanja dostupnosti lekova u Srbiji. Kako bi se pokazala sadašnja farmakoekonomska prednost leka neophodno je sprovesti analizu uticaja na budžet i analizu troškovne isplativosti. Drugu analizu je neophodno sprovesti primenom odgovarajuće tehnike modelovanja. Međutim, kako ne postoje zvanične smernice o modelovanju i ekonomskim evaluacija, dokumentacija podneta od strane nosioca dozvole pokazuje značajno variranje. Budućnost modelovanja u farmakoekonomiji zavisi od istraživačkog interesa, pri čemu se razvijaju novi okviri i pristupi.",
publisher = "Beograd : Savez farmaceutskih udruženja Srbije",
journal = "Arhiv za farmaciju",
title = "Modelling in economic evaluations of medicines, Modelovanje u farmakoekonomskim evaluacijama lekova",
volume = "71",
number = "4",
pages = "354-364",
doi = "10.5937/arhfarm71-32404"
}

Lakić, D., Stević, I., Odalović, M.,& Tadić, I.. (2021). Modelling in economic evaluations of medicines. in Arhiv za farmaciju
Beograd : Savez farmaceutskih udruženja Srbije., 71(4), 354-364.
https://doi.org/10.5937/arhfarm71-32404

Lakić D, Stević I, Odalović M, Tadić I. Modelling in economic evaluations of medicines. in Arhiv za farmaciju. 2021;71(4):354-364.
doi:10.5937/arhfarm71-32404 .

Lakić, Dragana, Stević, Ivana, Odalović, Marina, Tadić, Ivana, "Modelling in economic evaluations of medicines" in Arhiv za farmaciju, 71, no. 4 (2021):354-364,
https://doi.org/10.5937/arhfarm71-32404 . .

TY  - CONF
AU  - Tadić, Ivana
AU  - Tasić, Ljiljana
AU  - Odalović, Marina
AU  - Lakić, Dragana
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3373
PB  - Springer
C3  - International Journal of Clinical Pharmacy
T1  - Analysis of pharmaceutical care services in Serbian community pharmacies: comparative study
VL  - 41
IS  - 2
SP  - 609
EP  - 609
DO  - 10.1007/s11096-019-00805-7
ER  - 

@conference{
author = "Tadić, Ivana and Tasić, Ljiljana and Odalović, Marina and Lakić, Dragana",
year = "2019",
publisher = "Springer",
journal = "International Journal of Clinical Pharmacy",
title = "Analysis of pharmaceutical care services in Serbian community pharmacies: comparative study",
volume = "41",
number = "2",
pages = "609-609",
doi = "10.1007/s11096-019-00805-7"
}

Tadić, I., Tasić, L., Odalović, M.,& Lakić, D.. (2019). Analysis of pharmaceutical care services in Serbian community pharmacies: comparative study. in International Journal of Clinical Pharmacy
Springer., 41(2), 609-609.
https://doi.org/10.1007/s11096-019-00805-7

Tadić I, Tasić L, Odalović M, Lakić D. Analysis of pharmaceutical care services in Serbian community pharmacies: comparative study. in International Journal of Clinical Pharmacy. 2019;41(2):609-609.
doi:10.1007/s11096-019-00805-7 .

Tadić, Ivana, Tasić, Ljiljana, Odalović, Marina, Lakić, Dragana, "Analysis of pharmaceutical care services in Serbian community pharmacies: comparative study" in International Journal of Clinical Pharmacy, 41, no. 2 (2019):609-609,
https://doi.org/10.1007/s11096-019-00805-7 . .

TY  - CONF
AU  - Tadić, Ivana
AU  - Tasić, Ljiljana
AU  - Bošković, Isidora
AU  - Mijatović, Stefan
AU  - Jović, Sanja
AU  - Odalović, Marina
AU  - Lakić, Dragana
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4236
AB  - Pacijenti starije životne dobi primenjuju uglavnom veliki broj lekova. Tokom procesa izdavanja lekova i savetovanja pacijenata farmaceuti mogu značajno da doprinesu racionalnoj upotrebi lekova. Cilj ovog istraživanja bio je da se ispitaju stavovi farmaceuta o uslugama savetovanja starijih pacijenata o primeni lekova. Istraživanje je sprovedeno tokom 2018. godine u više lanaca apoteka u Srbiji uz pomoć namenski kreiranog on‐line upitnika. Upitnike su popunjavali samo farmaceuti. U istraživanju je učestvovalo 154 farmaceuta, pretežno ženskog pola (87,1%), prosečne starosti 38,3 godina i radnog staža 12,8 godina. Kada su u pitanju informacije o lekovima, pacijenti najviše veruju lekarima specijalistima (39,6%), farmaceutima (31,2%), lekarima opšte prakse (18,8%), i ljudima iz njihovog okruženja (10,4%). Farmaceuti najčešće pružaju informacije o upotrebi lekova (100,0%), indikacijama za upotrebu lekova (91,6%), dužini primene leka (77,9%), interakcijama sa hranom i lekovima (72,7%) i neželjenim reakcijama na lek (53,2%). Gužva u apoteci je najčešća (73,6%) barijera za adekvatno savetovanje pacijenata prepoznata od strane farmaceuta. Oko polovine farmaceuta (51,6%) smatra da usluga savetovanja starijih pacijenata treba da bude plaćena. Farmaceuti imaju jasan stav da je usluga savetovanja starijih pacijenata o primeni lekova od velikog značaja za kvalitet zdravstvene zaštite. Ovakva vrsta analize može pružiti smernice kako da se razviju farmaceutske usluge i kako da se implementiraju u svakodnevnoj praksi.
AB  - Elderly patients mostly use a large number of medicines. Pharmacists can contribute significantly to the rational use of medicines during the process of dispensing medicines and patient counseling. The aim of this study was to examine the attitudes of pharmacists about the services of counseling elderly patients on the safe use of medicines. The study was conducted in 2018 within several pharmacy chains in Serbia using on‐line questionnaire designed for this research. The questionnaires were filled out only by pharmacists. The study included 154 pharmacists, mostly female (87.1%), aged 38.3 years and 12.8 years of service in average. When it comes to information on medicines, patients mostly trust physicians (39.6%), pharmacists (31.2%), general practitioners (18.8%) and friends (10.4%). Pharmacists often provide information on medicines use
(100.0%), indications (91.6%), duration of administration (77.9%), medicines interactions with food and other medicines (72.7%) and adverse drug reactions (53.2%). The most common barrier for adequate counseling of patients recognized by pharmacist was crowded pharmacy (73.6%). About half of pharmacists (51.6%) think that elderly patient counseling services should be paid. Pharmacists think that the counseling service of elderly patients about safe use of medicines is of great importance for the quality of health care. This type of analysis can provide guidance on how to develop and implement pharmaceutical services.
PB  - Beograd : Savez fakmaceutskih udruženja Srbije
C3  - Arhiv za farmaciju
T1  - Pružanje usluge savetovanja starijih pacijenata o primeni Lekova – stavovi farmaceuta
T1  - Provision of pharmaceutical service to elderly patients about safe use of medicines ‐ the attitudes of pharmacists
VL  - 68
IS  - 3
SP  - 749
EP  - 750
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4236
ER  - 

@conference{
author = "Tadić, Ivana and Tasić, Ljiljana and Bošković, Isidora and Mijatović, Stefan and Jović, Sanja and Odalović, Marina and Lakić, Dragana",
year = "2018",
abstract = "Pacijenti starije životne dobi primenjuju uglavnom veliki broj lekova. Tokom procesa izdavanja lekova i savetovanja pacijenata farmaceuti mogu značajno da doprinesu racionalnoj upotrebi lekova. Cilj ovog istraživanja bio je da se ispitaju stavovi farmaceuta o uslugama savetovanja starijih pacijenata o primeni lekova. Istraživanje je sprovedeno tokom 2018. godine u više lanaca apoteka u Srbiji uz pomoć namenski kreiranog on‐line upitnika. Upitnike su popunjavali samo farmaceuti. U istraživanju je učestvovalo 154 farmaceuta, pretežno ženskog pola (87,1%), prosečne starosti 38,3 godina i radnog staža 12,8 godina. Kada su u pitanju informacije o lekovima, pacijenti najviše veruju lekarima specijalistima (39,6%), farmaceutima (31,2%), lekarima opšte prakse (18,8%), i ljudima iz njihovog okruženja (10,4%). Farmaceuti najčešće pružaju informacije o upotrebi lekova (100,0%), indikacijama za upotrebu lekova (91,6%), dužini primene leka (77,9%), interakcijama sa hranom i lekovima (72,7%) i neželjenim reakcijama na lek (53,2%). Gužva u apoteci je najčešća (73,6%) barijera za adekvatno savetovanje pacijenata prepoznata od strane farmaceuta. Oko polovine farmaceuta (51,6%) smatra da usluga savetovanja starijih pacijenata treba da bude plaćena. Farmaceuti imaju jasan stav da je usluga savetovanja starijih pacijenata o primeni lekova od velikog značaja za kvalitet zdravstvene zaštite. Ovakva vrsta analize može pružiti smernice kako da se razviju farmaceutske usluge i kako da se implementiraju u svakodnevnoj praksi., Elderly patients mostly use a large number of medicines. Pharmacists can contribute significantly to the rational use of medicines during the process of dispensing medicines and patient counseling. The aim of this study was to examine the attitudes of pharmacists about the services of counseling elderly patients on the safe use of medicines. The study was conducted in 2018 within several pharmacy chains in Serbia using on‐line questionnaire designed for this research. The questionnaires were filled out only by pharmacists. The study included 154 pharmacists, mostly female (87.1%), aged 38.3 years and 12.8 years of service in average. When it comes to information on medicines, patients mostly trust physicians (39.6%), pharmacists (31.2%), general practitioners (18.8%) and friends (10.4%). Pharmacists often provide information on medicines use
(100.0%), indications (91.6%), duration of administration (77.9%), medicines interactions with food and other medicines (72.7%) and adverse drug reactions (53.2%). The most common barrier for adequate counseling of patients recognized by pharmacist was crowded pharmacy (73.6%). About half of pharmacists (51.6%) think that elderly patient counseling services should be paid. Pharmacists think that the counseling service of elderly patients about safe use of medicines is of great importance for the quality of health care. This type of analysis can provide guidance on how to develop and implement pharmaceutical services.",
publisher = "Beograd : Savez fakmaceutskih udruženja Srbije",
journal = "Arhiv za farmaciju",
title = "Pružanje usluge savetovanja starijih pacijenata o primeni Lekova – stavovi farmaceuta, Provision of pharmaceutical service to elderly patients about safe use of medicines ‐ the attitudes of pharmacists",
volume = "68",
number = "3",
pages = "749-750",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4236"
}

Tadić, I., Tasić, L., Bošković, I., Mijatović, S., Jović, S., Odalović, M.,& Lakić, D.. (2018). Pružanje usluge savetovanja starijih pacijenata o primeni Lekova – stavovi farmaceuta. in Arhiv za farmaciju
Beograd : Savez fakmaceutskih udruženja Srbije., 68(3), 749-750.
https://hdl.handle.net/21.15107/rcub_farfar_4236

Tadić I, Tasić L, Bošković I, Mijatović S, Jović S, Odalović M, Lakić D. Pružanje usluge savetovanja starijih pacijenata o primeni Lekova – stavovi farmaceuta. in Arhiv za farmaciju. 2018;68(3):749-750.
https://hdl.handle.net/21.15107/rcub_farfar_4236 .

Tadić, Ivana, Tasić, Ljiljana, Bošković, Isidora, Mijatović, Stefan, Jović, Sanja, Odalović, Marina, Lakić, Dragana, "Pružanje usluge savetovanja starijih pacijenata o primeni Lekova – stavovi farmaceuta" in Arhiv za farmaciju, 68, no. 3 (2018):749-750,
https://hdl.handle.net/21.15107/rcub_farfar_4236 .

TY  - CONF
AU  - Plazinić, Tatjana
AU  - Tadić, Ivana
AU  - Odalović, Marina
AU  - Tasić, Ljiljana
AU  - Lakić, Dragana
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4218
AB  - Preporuka za lečenje blažih zdravstvenih tegoba i savetovanje za upotrebu lekova koji se izdaju bez lekarskog recepta je obaveza farmaceuta. Ovo istraživanje urađeno je sa ciljem da se uporede stavovi pacijenata i upotreba BR lekova u 2014. i 2018. godini. Istraživanje sa pacijentima Apoteke Beograd sprovedeno 2014. godine ponovljeno je u maju 2018. godine prateći istu metodologiju. U istraživanju je korišćen isti upitnik kreiran za potrebe ovog istraživanja. Pacijenti su samostalno i dobrovoljno popunjavali upitnik. U ponovljenom istraživanju učestvovao je veći broj pacijenata (90 vs. 57) starije životne dobi ( x =65,716,5 vs. x =47,617,2 godina). Veći broj pacijenata bio je ženskog pola (57,8% vs. 38,6%) sa manjom zastupljenošću hroničnih bolesti (30,0% vs. 42,1%). I dalje najveći procenat pacijenata kupuje BR lekove jednom mesečno ili češće (46,7% vs. 50,9%). Uticaj farmaceuta na izbor leka opao je tokom ovog perioda (36,7% vs. 57,1%), dok je uticaj lekara povećan (38,9% vs. 32,1%). Kao i u prethodnom istraživanju pacijenti su najčešće koristili BR lekove za bolove i probleme digestivnog trakta. Takođe, BR lekove se najčešće koriste na prvi znak bolesti, a najređe ako je bolest veoma ozbiljna. U oba istraživanja najveći broj pacijenata smatrao je da BR lekovi ne dovode do ozbiljnih neželjenih reakcija (57,8% vs. 42,1%) i da su potpuno bezbedni za upotrebu (56,7% vs. 43,9%). Ponovljeno istraživanje pokazalo je da pacijenti manje koriste BR lekove u odnosu na prethodni period. Uticaj farmaceuta na izbor leka je smanjen za razliku od uticaja lekara. Dalja istraživanja bi trebalo da se baziraju na detaljnije ispitivanje da li pacijenti imaju bolju zdravstvenu pismenost ili se poverenje u farmaceute smanjuje kada je u pitanju izbor BR leka.
AB  - Recommending effective minor ailment treatments and using non‐prescription medicines (NPM) is a pharmacist's duty. The aim of this study was to compare results of the studies about patients’ attitudes and NPM use conducted in 2014 and 2018 year. The research conducted in 2014 year was repeated in 2018 year using the same self‐administered questionnaire and methodology. More patients participated in the repeated research (90 vs. 57). They were older ( x =65.716.5 vs. x =47.617.2 year), mostly female gender (57.8% vs. 38.6%) and with less chronically diseases (30.0% vs. 42.1%) compared to the results of the previous research. Still, the most patients buy the NPM once a month or more often (46.7% vs. 50.9%). The influence of the pharmacists in the NPM selection was lesser (36.7% vs. 57.1%)while the influence of the doctors was bigger (38.9% vs. 32.1%). As in the previous research, patients mostly use NPM for pain and gastro‐intestinal problems. Also, the most of the patients use the NPM at the first sign of illness and the least if the disease is very serious. In both researches the most patients think that NPM can not cause serious adverse drug reactions (57.8% vs. 42.1%) and that NPM are safe medicines (56.7% vs. 43.9%).
The repeated research indicated that patients use less NPM medicines. The influence of the pharmacists in NPM choice was reduced unlike the influence of the doctors. Further research should examine the NPM use with the aspects of heath literacy of the patients and patients' confidence in their pharmacists.
PB  - Beograd : Savez fakmaceutskih udruženja Srbije
C3  - Arhiv za farmaciju
T1  - Stavovi pacijenata i upotreba lekova bez lekarskog recepta na teritoriji grada beograda –analiza promena i trendova
T1  - Attitudes of patients and usage of non‐prescription medicines in Belgrade – changes over the last four years
VL  - 68
IS  - 3
SP  - 751
EP  - 752
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4218
ER  - 

@conference{
author = "Plazinić, Tatjana and Tadić, Ivana and Odalović, Marina and Tasić, Ljiljana and Lakić, Dragana",
year = "2018",
abstract = "Preporuka za lečenje blažih zdravstvenih tegoba i savetovanje za upotrebu lekova koji se izdaju bez lekarskog recepta je obaveza farmaceuta. Ovo istraživanje urađeno je sa ciljem da se uporede stavovi pacijenata i upotreba BR lekova u 2014. i 2018. godini. Istraživanje sa pacijentima Apoteke Beograd sprovedeno 2014. godine ponovljeno je u maju 2018. godine prateći istu metodologiju. U istraživanju je korišćen isti upitnik kreiran za potrebe ovog istraživanja. Pacijenti su samostalno i dobrovoljno popunjavali upitnik. U ponovljenom istraživanju učestvovao je veći broj pacijenata (90 vs. 57) starije životne dobi ( x =65,716,5 vs. x =47,617,2 godina). Veći broj pacijenata bio je ženskog pola (57,8% vs. 38,6%) sa manjom zastupljenošću hroničnih bolesti (30,0% vs. 42,1%). I dalje najveći procenat pacijenata kupuje BR lekove jednom mesečno ili češće (46,7% vs. 50,9%). Uticaj farmaceuta na izbor leka opao je tokom ovog perioda (36,7% vs. 57,1%), dok je uticaj lekara povećan (38,9% vs. 32,1%). Kao i u prethodnom istraživanju pacijenti su najčešće koristili BR lekove za bolove i probleme digestivnog trakta. Takođe, BR lekove se najčešće koriste na prvi znak bolesti, a najređe ako je bolest veoma ozbiljna. U oba istraživanja najveći broj pacijenata smatrao je da BR lekovi ne dovode do ozbiljnih neželjenih reakcija (57,8% vs. 42,1%) i da su potpuno bezbedni za upotrebu (56,7% vs. 43,9%). Ponovljeno istraživanje pokazalo je da pacijenti manje koriste BR lekove u odnosu na prethodni period. Uticaj farmaceuta na izbor leka je smanjen za razliku od uticaja lekara. Dalja istraživanja bi trebalo da se baziraju na detaljnije ispitivanje da li pacijenti imaju bolju zdravstvenu pismenost ili se poverenje u farmaceute smanjuje kada je u pitanju izbor BR leka., Recommending effective minor ailment treatments and using non‐prescription medicines (NPM) is a pharmacist's duty. The aim of this study was to compare results of the studies about patients’ attitudes and NPM use conducted in 2014 and 2018 year. The research conducted in 2014 year was repeated in 2018 year using the same self‐administered questionnaire and methodology. More patients participated in the repeated research (90 vs. 57). They were older ( x =65.716.5 vs. x =47.617.2 year), mostly female gender (57.8% vs. 38.6%) and with less chronically diseases (30.0% vs. 42.1%) compared to the results of the previous research. Still, the most patients buy the NPM once a month or more often (46.7% vs. 50.9%). The influence of the pharmacists in the NPM selection was lesser (36.7% vs. 57.1%)while the influence of the doctors was bigger (38.9% vs. 32.1%). As in the previous research, patients mostly use NPM for pain and gastro‐intestinal problems. Also, the most of the patients use the NPM at the first sign of illness and the least if the disease is very serious. In both researches the most patients think that NPM can not cause serious adverse drug reactions (57.8% vs. 42.1%) and that NPM are safe medicines (56.7% vs. 43.9%).
The repeated research indicated that patients use less NPM medicines. The influence of the pharmacists in NPM choice was reduced unlike the influence of the doctors. Further research should examine the NPM use with the aspects of heath literacy of the patients and patients' confidence in their pharmacists.",
publisher = "Beograd : Savez fakmaceutskih udruženja Srbije",
journal = "Arhiv za farmaciju",
title = "Stavovi pacijenata i upotreba lekova bez lekarskog recepta na teritoriji grada beograda –analiza promena i trendova, Attitudes of patients and usage of non‐prescription medicines in Belgrade – changes over the last four years",
volume = "68",
number = "3",
pages = "751-752",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4218"
}

Plazinić, T., Tadić, I., Odalović, M., Tasić, L.,& Lakić, D.. (2018). Stavovi pacijenata i upotreba lekova bez lekarskog recepta na teritoriji grada beograda –analiza promena i trendova. in Arhiv za farmaciju
Beograd : Savez fakmaceutskih udruženja Srbije., 68(3), 751-752.
https://hdl.handle.net/21.15107/rcub_farfar_4218

Plazinić T, Tadić I, Odalović M, Tasić L, Lakić D. Stavovi pacijenata i upotreba lekova bez lekarskog recepta na teritoriji grada beograda –analiza promena i trendova. in Arhiv za farmaciju. 2018;68(3):751-752.
https://hdl.handle.net/21.15107/rcub_farfar_4218 .

Plazinić, Tatjana, Tadić, Ivana, Odalović, Marina, Tasić, Ljiljana, Lakić, Dragana, "Stavovi pacijenata i upotreba lekova bez lekarskog recepta na teritoriji grada beograda –analiza promena i trendova" in Arhiv za farmaciju, 68, no. 3 (2018):751-752,
https://hdl.handle.net/21.15107/rcub_farfar_4218 .

TY  - CONF
AU  - Lakić, Dragana
AU  - Odalović, Marina
AU  - Jakovljević, Vladimir
AU  - Arsić, Ivana A.
AU  - Komazec, Zoran
AU  - Tasić, Ljiljana
AU  - Parojčić, Jelena
AU  - Cavaco, Afonso
AU  - Henman, Martin
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3179
PB  - Springer
C3  - International Journal of Clinical Pharmacy
T1  - Advancement in pharmacy education-professional practice in university curricula in Serbia
VL  - 40
IS  - 1
SP  - 242
EP  - 243
DO  - 10.1007/s11096-017-0565-9
ER  - 

@conference{
author = "Lakić, Dragana and Odalović, Marina and Jakovljević, Vladimir and Arsić, Ivana A. and Komazec, Zoran and Tasić, Ljiljana and Parojčić, Jelena and Cavaco, Afonso and Henman, Martin",
year = "2018",
publisher = "Springer",
journal = "International Journal of Clinical Pharmacy",
title = "Advancement in pharmacy education-professional practice in university curricula in Serbia",
volume = "40",
number = "1",
pages = "242-243",
doi = "10.1007/s11096-017-0565-9"
}

Lakić, D., Odalović, M., Jakovljević, V., Arsić, I. A., Komazec, Z., Tasić, L., Parojčić, J., Cavaco, A.,& Henman, M.. (2018). Advancement in pharmacy education-professional practice in university curricula in Serbia. in International Journal of Clinical Pharmacy
Springer., 40(1), 242-243.
https://doi.org/10.1007/s11096-017-0565-9

Lakić D, Odalović M, Jakovljević V, Arsić IA, Komazec Z, Tasić L, Parojčić J, Cavaco A, Henman M. Advancement in pharmacy education-professional practice in university curricula in Serbia. in International Journal of Clinical Pharmacy. 2018;40(1):242-243.
doi:10.1007/s11096-017-0565-9 .

Lakić, Dragana, Odalović, Marina, Jakovljević, Vladimir, Arsić, Ivana A., Komazec, Zoran, Tasić, Ljiljana, Parojčić, Jelena, Cavaco, Afonso, Henman, Martin, "Advancement in pharmacy education-professional practice in university curricula in Serbia" in International Journal of Clinical Pharmacy, 40, no. 1 (2018):242-243,
https://doi.org/10.1007/s11096-017-0565-9 . .

TY  - JOUR
AU  - Lakić, Dragana
AU  - Travica, Jovana
AU  - Odalović, Marina
AU  - Tadić, Ivana
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3030
AB  - Venous thromboembolism, including pulmonary embolism and deep vein thrombosis, is a signifi cant factor in morbidity and mortality of patients. New oral anticoagulants, such as apixaban, dabigatran, and rivaroxaban, have recently demonstrated their safety and efficacy in patients undergoing major orthopaedic surgery. Selection of the appropriate drug should be adjusted according to patient needs. Major bleeding is rare with new oral anticoagulants and is comparable with the bleeding rate associated with low-molecular-weight heparins. Clinical data indicate that therapy with apixaban and rivaroxaban was more effective compared to enoxaparin, while dabigatran has a similar efficacy to enoxaparin. Cost-effectiveness studies of new oral anticoagulants showed that these medicines offer higher efficacy with acceptable costs for the healthcare system, even saving costs in certain cases. Clinical practice in Serbia reflects considerably more frequent use of traditional anticoagulant medication therapy compared to new oral anticoagulants.
AB  - Venska tromboembolija, koja uključuje plućnu emboliju i duboku vensku trombozu, predstavlja značajan faktor morbiditeta i mortaliteta pacijenata. Novi oralni antikoagulansi, poput apiksabana, dabigatrana i rivaroksabana, su nedavno pokazali svoju bezbednost i efikasnost kod pacijenata koji se podvrgavaju velikim ortopedskim intervencijama. Izbor odgovarajućeg leka treba prilagoditi individualnim potrebama pacijenta. Velika krvarenja su relativno retka u toku primene novih oralnih antikoagulanasa i uporedivi su sa stopom krvarenja prilikom primene nisko-molekularnih heparina. Klinički podaci ukazuju da je terapija apiksabanom i rivarokabanom efikasnija u odnosu na enoksaparin, dok dabigatran ima slične efekte kao enoksaparin. Troškovna isplativost novih oralnih antikoagulanasa potvrđuje veću efikasnost sa prihvatljivim troškovima za zdravstveni sistem, u nekim slučajevima čak i sa uštedama.
PB  - Univerzitet u Kragujevcu - Fakultet medicinskih nauka, Kragujevac
T2  - Serbian Journal of Experimental and Clinical Research
T1  - Clinical and economic outcomes of new oral anticoagulants in orthopaedics
T1  - Klinički i ekonomski ishodi primene novih oralnih antikoagulanasa u ortopediji
VL  - 19
IS  - 1
SP  - 3
EP  - 9
DO  - 10.1515/SJECR-2017-0066
ER  - 

@article{
author = "Lakić, Dragana and Travica, Jovana and Odalović, Marina and Tadić, Ivana",
year = "2018",
abstract = "Venous thromboembolism, including pulmonary embolism and deep vein thrombosis, is a signifi cant factor in morbidity and mortality of patients. New oral anticoagulants, such as apixaban, dabigatran, and rivaroxaban, have recently demonstrated their safety and efficacy in patients undergoing major orthopaedic surgery. Selection of the appropriate drug should be adjusted according to patient needs. Major bleeding is rare with new oral anticoagulants and is comparable with the bleeding rate associated with low-molecular-weight heparins. Clinical data indicate that therapy with apixaban and rivaroxaban was more effective compared to enoxaparin, while dabigatran has a similar efficacy to enoxaparin. Cost-effectiveness studies of new oral anticoagulants showed that these medicines offer higher efficacy with acceptable costs for the healthcare system, even saving costs in certain cases. Clinical practice in Serbia reflects considerably more frequent use of traditional anticoagulant medication therapy compared to new oral anticoagulants., Venska tromboembolija, koja uključuje plućnu emboliju i duboku vensku trombozu, predstavlja značajan faktor morbiditeta i mortaliteta pacijenata. Novi oralni antikoagulansi, poput apiksabana, dabigatrana i rivaroksabana, su nedavno pokazali svoju bezbednost i efikasnost kod pacijenata koji se podvrgavaju velikim ortopedskim intervencijama. Izbor odgovarajućeg leka treba prilagoditi individualnim potrebama pacijenta. Velika krvarenja su relativno retka u toku primene novih oralnih antikoagulanasa i uporedivi su sa stopom krvarenja prilikom primene nisko-molekularnih heparina. Klinički podaci ukazuju da je terapija apiksabanom i rivarokabanom efikasnija u odnosu na enoksaparin, dok dabigatran ima slične efekte kao enoksaparin. Troškovna isplativost novih oralnih antikoagulanasa potvrđuje veću efikasnost sa prihvatljivim troškovima za zdravstveni sistem, u nekim slučajevima čak i sa uštedama.",
publisher = "Univerzitet u Kragujevcu - Fakultet medicinskih nauka, Kragujevac",
journal = "Serbian Journal of Experimental and Clinical Research",
title = "Clinical and economic outcomes of new oral anticoagulants in orthopaedics, Klinički i ekonomski ishodi primene novih oralnih antikoagulanasa u ortopediji",
volume = "19",
number = "1",
pages = "3-9",
doi = "10.1515/SJECR-2017-0066"
}

Lakić, D., Travica, J., Odalović, M.,& Tadić, I.. (2018). Clinical and economic outcomes of new oral anticoagulants in orthopaedics. in Serbian Journal of Experimental and Clinical Research
Univerzitet u Kragujevcu - Fakultet medicinskih nauka, Kragujevac., 19(1), 3-9.
https://doi.org/10.1515/SJECR-2017-0066

Lakić D, Travica J, Odalović M, Tadić I. Clinical and economic outcomes of new oral anticoagulants in orthopaedics. in Serbian Journal of Experimental and Clinical Research. 2018;19(1):3-9.
doi:10.1515/SJECR-2017-0066 .

Lakić, Dragana, Travica, Jovana, Odalović, Marina, Tadić, Ivana, "Clinical and economic outcomes of new oral anticoagulants in orthopaedics" in Serbian Journal of Experimental and Clinical Research, 19, no. 1 (2018):3-9,
https://doi.org/10.1515/SJECR-2017-0066 . .

TY  - JOUR
AU  - Kamusheva, Maria
AU  - Manova, Manoela
AU  - Savova, Alexandra
AU  - Petrova, Guenka
AU  - Mitov, Konstantin
AU  - Harsanyi, Andras
AU  - Kalo, Zoltan
AU  - Marky, Kristof
AU  - Kawalec, Pawel
AU  - Angelovska, Bistra
AU  - Lakić, Dragana
AU  - Tesar, Tomas
AU  - Draganić, Pero
AU  - Geitona, Mary
AU  - Hatziko, Magdalini
AU  - Paveliu, Marian S.
AU  - Mannik, Agnes
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3195
AB  - Objectives: The aim of the study was to compare the access of patients with rare diseases (RDs) to biotechnological drugs in several Central and Eastern European countries (CEECs). We focused on the legislative pricing and reimbursement requirements, availability of biotechnological orphan medicinal products (BOMPs) for RDs, and reimbursement expenditures. Methods: A questionnaire-based survey was conducted among experts from 10 CEECs: Bulgaria, Croatia, Estonia, Greece, Hungary, Poland, Romania, Slovakia, Serbia, and Macedonia. The legal requirements for reimbursement and pricing of BOMPs were collected. All BOMPs and medicines without prior orphan designations were extracted from the European list of orphan medicinal products, 2017. The reimbursement status of these medicinal products in 2017 in the public coverage of the included CEECs as well as the share of their costs in relation to the total public pharmaceutical spending for the period from 2014 to 2016 were defined. Results: Our survey revealed that some differences in the legal requirements for pricing and reimbursement of BOMPs amongst the countries included in the study. All European Union countries have developed and implemented pharmacoeconomic guidelines with or without some specific reimbursement requirements for orphan medicinal products. Cost-effectiveness analysis, cost-utility analysis, Markov models, meta-analysis, and discount levels of costs and results were required only in Bulgaria, Poland and Hungary. The number of reimbursed BOMPs and biotechnological medicinal products for RDs without prior orphan designation was the highest in Hungary (17 and 40, respectively). Patient-based reimbursement schemes were available only in Hungary for 11 out of 17 BOMPs. Poland and Greece have the highest pharmaceutical expenditure of reimbursed BOMPs with are similar to 214 million and 180 million EUR, respectively in the observed period from 2014 to 2016. High proportion of the pharmaceutical expenditure on the reimbursed biotechnological medicinal products for RDs for the observed period 2014-2016 is presented in Bulgaria and Slovakia. Conclusions: The non-European Union CEECs face a significant delay in the legal implementation of pharmacoeconomic guideline for assessment of BOMPs. The access to BOMPs is similar among the observed CEECs and the countries with the best access are Hungary and Greece. The influence of BOMP expenditures on the budget in the individual countries is significant.
PB  - Frontiers Media Sa, Lausanne
T2  - Frontiers in Pharmacology
T1  - Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries
VL  - 9
DO  - 10.3389/fphar.2018.00795
ER  - 

@article{
author = "Kamusheva, Maria and Manova, Manoela and Savova, Alexandra and Petrova, Guenka and Mitov, Konstantin and Harsanyi, Andras and Kalo, Zoltan and Marky, Kristof and Kawalec, Pawel and Angelovska, Bistra and Lakić, Dragana and Tesar, Tomas and Draganić, Pero and Geitona, Mary and Hatziko, Magdalini and Paveliu, Marian S. and Mannik, Agnes",
year = "2018",
abstract = "Objectives: The aim of the study was to compare the access of patients with rare diseases (RDs) to biotechnological drugs in several Central and Eastern European countries (CEECs). We focused on the legislative pricing and reimbursement requirements, availability of biotechnological orphan medicinal products (BOMPs) for RDs, and reimbursement expenditures. Methods: A questionnaire-based survey was conducted among experts from 10 CEECs: Bulgaria, Croatia, Estonia, Greece, Hungary, Poland, Romania, Slovakia, Serbia, and Macedonia. The legal requirements for reimbursement and pricing of BOMPs were collected. All BOMPs and medicines without prior orphan designations were extracted from the European list of orphan medicinal products, 2017. The reimbursement status of these medicinal products in 2017 in the public coverage of the included CEECs as well as the share of their costs in relation to the total public pharmaceutical spending for the period from 2014 to 2016 were defined. Results: Our survey revealed that some differences in the legal requirements for pricing and reimbursement of BOMPs amongst the countries included in the study. All European Union countries have developed and implemented pharmacoeconomic guidelines with or without some specific reimbursement requirements for orphan medicinal products. Cost-effectiveness analysis, cost-utility analysis, Markov models, meta-analysis, and discount levels of costs and results were required only in Bulgaria, Poland and Hungary. The number of reimbursed BOMPs and biotechnological medicinal products for RDs without prior orphan designation was the highest in Hungary (17 and 40, respectively). Patient-based reimbursement schemes were available only in Hungary for 11 out of 17 BOMPs. Poland and Greece have the highest pharmaceutical expenditure of reimbursed BOMPs with are similar to 214 million and 180 million EUR, respectively in the observed period from 2014 to 2016. High proportion of the pharmaceutical expenditure on the reimbursed biotechnological medicinal products for RDs for the observed period 2014-2016 is presented in Bulgaria and Slovakia. Conclusions: The non-European Union CEECs face a significant delay in the legal implementation of pharmacoeconomic guideline for assessment of BOMPs. The access to BOMPs is similar among the observed CEECs and the countries with the best access are Hungary and Greece. The influence of BOMP expenditures on the budget in the individual countries is significant.",
publisher = "Frontiers Media Sa, Lausanne",
journal = "Frontiers in Pharmacology",
title = "Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries",
volume = "9",
doi = "10.3389/fphar.2018.00795"
}

Kamusheva, M., Manova, M., Savova, A., Petrova, G., Mitov, K., Harsanyi, A., Kalo, Z., Marky, K., Kawalec, P., Angelovska, B., Lakić, D., Tesar, T., Draganić, P., Geitona, M., Hatziko, M., Paveliu, M. S.,& Mannik, A.. (2018). Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries. in Frontiers in Pharmacology
Frontiers Media Sa, Lausanne., 9.
https://doi.org/10.3389/fphar.2018.00795

Kamusheva M, Manova M, Savova A, Petrova G, Mitov K, Harsanyi A, Kalo Z, Marky K, Kawalec P, Angelovska B, Lakić D, Tesar T, Draganić P, Geitona M, Hatziko M, Paveliu MS, Mannik A. Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries. in Frontiers in Pharmacology. 2018;9.
doi:10.3389/fphar.2018.00795 .

Kamusheva, Maria, Manova, Manoela, Savova, Alexandra, Petrova, Guenka, Mitov, Konstantin, Harsanyi, Andras, Kalo, Zoltan, Marky, Kristof, Kawalec, Pawel, Angelovska, Bistra, Lakić, Dragana, Tesar, Tomas, Draganić, Pero, Geitona, Mary, Hatziko, Magdalini, Paveliu, Marian S., Mannik, Agnes, "Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries" in Frontiers in Pharmacology, 9 (2018),
https://doi.org/10.3389/fphar.2018.00795 . .

TY  - CONF
AU  - Lakić, Dragana
AU  - Odalović, Marina
AU  - Stević, Ivana
AU  - Vezmar-Kovačević, Sandra
AU  - Tadić, Ivana
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3020
PB  - Springer
C3  - International Journal of Clinical Pharmacy
T1  - Willingness to pay for cognitive pharmacy service in community pharmacies
VL  - 39
IS  - 3
SP  - 603
EP  - 603
DO  - 10.1007/s11096-017-0462-2
ER  - 

@conference{
author = "Lakić, Dragana and Odalović, Marina and Stević, Ivana and Vezmar-Kovačević, Sandra and Tadić, Ivana",
year = "2017",
publisher = "Springer",
journal = "International Journal of Clinical Pharmacy",
title = "Willingness to pay for cognitive pharmacy service in community pharmacies",
volume = "39",
number = "3",
pages = "603-603",
doi = "10.1007/s11096-017-0462-2"
}

Lakić, D., Odalović, M., Stević, I., Vezmar-Kovačević, S.,& Tadić, I.. (2017). Willingness to pay for cognitive pharmacy service in community pharmacies. in International Journal of Clinical Pharmacy
Springer., 39(3), 603-603.
https://doi.org/10.1007/s11096-017-0462-2

Lakić D, Odalović M, Stević I, Vezmar-Kovačević S, Tadić I. Willingness to pay for cognitive pharmacy service in community pharmacies. in International Journal of Clinical Pharmacy. 2017;39(3):603-603.
doi:10.1007/s11096-017-0462-2 .

Lakić, Dragana, Odalović, Marina, Stević, Ivana, Vezmar-Kovačević, Sandra, Tadić, Ivana, "Willingness to pay for cognitive pharmacy service in community pharmacies" in International Journal of Clinical Pharmacy, 39, no. 3 (2017):603-603,
https://doi.org/10.1007/s11096-017-0462-2 . .

TY  - JOUR
AU  - Lakić, Dragana
AU  - Stević, Ivana
AU  - Odalović, Marina
AU  - Vezmar-Kovačević, Sandra
AU  - Tadić, Ivana
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2852
AB  - Aim To determine the general population willingness to pay for cognitive pharmacist service in community pharmacy, describe the behavior of participants regarding health care issues, and evaluate correlation between participants' sociodemographic characteristics or attitudes and their willingness to pay. Methods A questionnaire-based survey was conducted among general population visiting community pharmacies. The participants were asked about receiving cognitive pharmacist services to identify and resolve potential medication therapy problems after the initiation of a new medicine to optimize health outcomes of the patients. A univariate and multivariate analysis were used to analyze associations between different variables and willingness to pay for pharmacy service. Results Of 444 respondents, 167 (38%) reported that they were willing to pay for a medication management service provided in the community pharmacy. Univariate analysis showed significant association between the willingness to pay for pharmacist-provided service and respondents' socio-demographic factors, health-related characteristics, and behavior, dilemmas, or need for certain pharmacist-provided service. The logistic regression model was statistically significant (chi(2) = 4.599, P  lt  0.001). Conclusions The respondents expressed their willingness to pay for cognitive pharmacist services, which has not been fully recognized within the health care system. In future, pharmacists should focus on practical implementation of the service and models of funding
PB  - Medicinska Naklada, Zagreb
T2  - Croatian Medical Journal
T1  - Patients' willingness to pay for cognitive pharmacist services in community pharmacies
VL  - 58
IS  - 5
SP  - 364
EP  - 371
DO  - 10.3325/cmj.2017.58.364
ER  - 

@article{
author = "Lakić, Dragana and Stević, Ivana and Odalović, Marina and Vezmar-Kovačević, Sandra and Tadić, Ivana",
year = "2017",
abstract = "Aim To determine the general population willingness to pay for cognitive pharmacist service in community pharmacy, describe the behavior of participants regarding health care issues, and evaluate correlation between participants' sociodemographic characteristics or attitudes and their willingness to pay. Methods A questionnaire-based survey was conducted among general population visiting community pharmacies. The participants were asked about receiving cognitive pharmacist services to identify and resolve potential medication therapy problems after the initiation of a new medicine to optimize health outcomes of the patients. A univariate and multivariate analysis were used to analyze associations between different variables and willingness to pay for pharmacy service. Results Of 444 respondents, 167 (38%) reported that they were willing to pay for a medication management service provided in the community pharmacy. Univariate analysis showed significant association between the willingness to pay for pharmacist-provided service and respondents' socio-demographic factors, health-related characteristics, and behavior, dilemmas, or need for certain pharmacist-provided service. The logistic regression model was statistically significant (chi(2) = 4.599, P  lt  0.001). Conclusions The respondents expressed their willingness to pay for cognitive pharmacist services, which has not been fully recognized within the health care system. In future, pharmacists should focus on practical implementation of the service and models of funding",
publisher = "Medicinska Naklada, Zagreb",
journal = "Croatian Medical Journal",
title = "Patients' willingness to pay for cognitive pharmacist services in community pharmacies",
volume = "58",
number = "5",
pages = "364-371",
doi = "10.3325/cmj.2017.58.364"
}

Lakić, D., Stević, I., Odalović, M., Vezmar-Kovačević, S.,& Tadić, I.. (2017). Patients' willingness to pay for cognitive pharmacist services in community pharmacies. in Croatian Medical Journal
Medicinska Naklada, Zagreb., 58(5), 364-371.
https://doi.org/10.3325/cmj.2017.58.364

Lakić D, Stević I, Odalović M, Vezmar-Kovačević S, Tadić I. Patients' willingness to pay for cognitive pharmacist services in community pharmacies. in Croatian Medical Journal. 2017;58(5):364-371.
doi:10.3325/cmj.2017.58.364 .

Lakić, Dragana, Stević, Ivana, Odalović, Marina, Vezmar-Kovačević, Sandra, Tadić, Ivana, "Patients' willingness to pay for cognitive pharmacist services in community pharmacies" in Croatian Medical Journal, 58, no. 5 (2017):364-371,
https://doi.org/10.3325/cmj.2017.58.364 . .

TY  - CONF
AU  - Stojković, Tatjana
AU  - Bogavac-Stanojević, Nataša
AU  - Marinković, Valentina
AU  - Lakić, Dragana
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2683
AB  - Objectives: A Pharmacist-Managed Warfarin Service (PMWS) is perceived as an
efficient method for improving anticoagulation control and decreasing the rate of
bleeding, thus reducing overall healthcare costs. What this study aims to assess is
a five-year budget impact of providing PMWS instead of Usual Medical Care (UMC)
to patients on warfarin at the secondary/tertiary level of healthcare facilities in
Serbia. Methods: A budget impact analysis was performed from the payer’s per-
spective (National Health Insurance Fund-NHIF), over a five-year time horizon. A
reference scenario (UMC) and a new one (PMWS) were defined for a cohort of 18,067
insured patients taking warfarin, with the pre-assumed annual population growth
rate of 20%, according to NHIF database. Direct medical costs included the acquisi-
tion costs of warfarin, blood products and drugs for anticoagulation reversal, as
well as hospitalization and monitoring. The expected values of annual therapy
were based on the probabilities of patient being well-controlled or hypercoagulated,
without any symptoms or with minor/major bleeding (pre-assumed incidence of
the adverse events was once in a year, during 10 days). Results: The projected net
cost savings have amounted to € 55,317, € 66,379, € 79,655, € 95,589 and € 114,704
for 2016, 2017, 2018, 2019 and 2020, respectively. Consequently, the total saving of €
411,644 could be achieved if PMWS was implemented, over a five-year period (2016-
2020), with a total budget reduction of 4.15%. The major economic benefits were
attributed to the decrease of hospitalization expenditures in case of PMWS, related
to the reduction of bleeding rates. ConClusions: Provision of PMWS instead of
UMC to patients on warfarin could result in substantial net budget savings, due to
improved both clinical and economic outcomes. Accordingly, this pharmaceutical
service has much to recommend it for the implementation in the healthcare system
of Serbia in the future.
PB  - Elsevier Science Inc
C3  - Value in Health
T1  - Budget impact analysis of introducing pharmacist-managed warfarin service in the republic of Serbia
VL  - 19
IS  - 7
SP  - A626
DO  - 10.1016/j.jval.2016.09.1610
ER  - 

@conference{
author = "Stojković, Tatjana and Bogavac-Stanojević, Nataša and Marinković, Valentina and Lakić, Dragana",
year = "2016",
abstract = "Objectives: A Pharmacist-Managed Warfarin Service (PMWS) is perceived as an
efficient method for improving anticoagulation control and decreasing the rate of
bleeding, thus reducing overall healthcare costs. What this study aims to assess is
a five-year budget impact of providing PMWS instead of Usual Medical Care (UMC)
to patients on warfarin at the secondary/tertiary level of healthcare facilities in
Serbia. Methods: A budget impact analysis was performed from the payer’s per-
spective (National Health Insurance Fund-NHIF), over a five-year time horizon. A
reference scenario (UMC) and a new one (PMWS) were defined for a cohort of 18,067
insured patients taking warfarin, with the pre-assumed annual population growth
rate of 20%, according to NHIF database. Direct medical costs included the acquisi-
tion costs of warfarin, blood products and drugs for anticoagulation reversal, as
well as hospitalization and monitoring. The expected values of annual therapy
were based on the probabilities of patient being well-controlled or hypercoagulated,
without any symptoms or with minor/major bleeding (pre-assumed incidence of
the adverse events was once in a year, during 10 days). Results: The projected net
cost savings have amounted to € 55,317, € 66,379, € 79,655, € 95,589 and € 114,704
for 2016, 2017, 2018, 2019 and 2020, respectively. Consequently, the total saving of €
411,644 could be achieved if PMWS was implemented, over a five-year period (2016-
2020), with a total budget reduction of 4.15%. The major economic benefits were
attributed to the decrease of hospitalization expenditures in case of PMWS, related
to the reduction of bleeding rates. ConClusions: Provision of PMWS instead of
UMC to patients on warfarin could result in substantial net budget savings, due to
improved both clinical and economic outcomes. Accordingly, this pharmaceutical
service has much to recommend it for the implementation in the healthcare system
of Serbia in the future.",
publisher = "Elsevier Science Inc",
journal = "Value in Health",
title = "Budget impact analysis of introducing pharmacist-managed warfarin service in the republic of Serbia",
volume = "19",
number = "7",
pages = "A626",
doi = "10.1016/j.jval.2016.09.1610"
}

Stojković, T., Bogavac-Stanojević, N., Marinković, V.,& Lakić, D.. (2016). Budget impact analysis of introducing pharmacist-managed warfarin service in the republic of Serbia. in Value in Health
Elsevier Science Inc., 19(7), A626.
https://doi.org/10.1016/j.jval.2016.09.1610

Stojković T, Bogavac-Stanojević N, Marinković V, Lakić D. Budget impact analysis of introducing pharmacist-managed warfarin service in the republic of Serbia. in Value in Health. 2016;19(7):A626.
doi:10.1016/j.jval.2016.09.1610 .

Stojković, Tatjana, Bogavac-Stanojević, Nataša, Marinković, Valentina, Lakić, Dragana, "Budget impact analysis of introducing pharmacist-managed warfarin service in the republic of Serbia" in Value in Health, 19, no. 7 (2016):A626,
https://doi.org/10.1016/j.jval.2016.09.1610 . .

TY  - CONF
AU  - Jocić, D. D.
AU  - Krajnović, Dušanka
AU  - Lakić, Dragana
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2681
AB  - Objectives: A number of socio - demographic factors influence the occurrence
of job burnout in community pharmacists. Aim is determine the relationship
between community pharmacist burnout degree with professional stress and
socio-damographic factors. Methods: This is a cross-sectional survey with
the convenient sample of 386 community pharmacists coming from all the
regions from the country. The questionnaire was administered to them at their
pharmacies or during a branch`s pharmacy meetings, following the drop-off/
pick up survey technique. The instrument was a five-point Likert type scale of
25 items. Descriptive statistics, Analysis of variance (ANOVA) and correlation
analysis were used for data analysis. Results: More than half of the respond-
ents stressed (62%), and 42% of pharmacists is at burnout risk. There is a high
degree of correlation between occupational stress and job burnout (r = 0.724, p
< 0.01). Job burnout risk is correlated with the following socio-demographic fac-
tors: the age pharmacist (r = 0.127, p < 0.01), pharmacists work experience (r =
0.138, p < 0.01), and the organization of shift work in pharmacies (r = - 0.312,
p < 0.01). ANOVA showed that, depending on whether they work alone in the
shift, with the one pharmacist in shift, with more pharmacists in shift, with
pharmaceutical technician in shift, pharmacists differ significantly according
to the risk of job burnout (F (3,382) = 61.013, p = 0.01) . Burnout risk increases
with age (F (4,381) = 2.575, p = 0.01), and work experience (F (3,382) = 6.080, p =
0.01). ConClusions: Job burnout risk is correlated with the degree of exposure
to professional stress, and increases with pharmacists age and work experience.
The greatest job burnout risk are pharmacists working alone in a shift and phar-
macists working with a pharmaceutical technician. The results indicate that
socio-demographic factors and exposure to professional stress lead to job burnout
PB  - Elsevier Science Inc
C3  - Value in Health
T1  - Job burnout predictors in community pharmacists in Serbia
VL  - 19
IS  - 7
IS  - 7
SP  - A475
DO  - 10.1016/j.jval.2016.09.746
ER  - 

@conference{
author = "Jocić, D. D. and Krajnović, Dušanka and Lakić, Dragana",
year = "2016",
abstract = "Objectives: A number of socio - demographic factors influence the occurrence
of job burnout in community pharmacists. Aim is determine the relationship
between community pharmacist burnout degree with professional stress and
socio-damographic factors. Methods: This is a cross-sectional survey with
the convenient sample of 386 community pharmacists coming from all the
regions from the country. The questionnaire was administered to them at their
pharmacies or during a branch`s pharmacy meetings, following the drop-off/
pick up survey technique. The instrument was a five-point Likert type scale of
25 items. Descriptive statistics, Analysis of variance (ANOVA) and correlation
analysis were used for data analysis. Results: More than half of the respond-
ents stressed (62%), and 42% of pharmacists is at burnout risk. There is a high
degree of correlation between occupational stress and job burnout (r = 0.724, p
< 0.01). Job burnout risk is correlated with the following socio-demographic fac-
tors: the age pharmacist (r = 0.127, p < 0.01), pharmacists work experience (r =
0.138, p < 0.01), and the organization of shift work in pharmacies (r = - 0.312,
p < 0.01). ANOVA showed that, depending on whether they work alone in the
shift, with the one pharmacist in shift, with more pharmacists in shift, with
pharmaceutical technician in shift, pharmacists differ significantly according
to the risk of job burnout (F (3,382) = 61.013, p = 0.01) . Burnout risk increases
with age (F (4,381) = 2.575, p = 0.01), and work experience (F (3,382) = 6.080, p =
0.01). ConClusions: Job burnout risk is correlated with the degree of exposure
to professional stress, and increases with pharmacists age and work experience.
The greatest job burnout risk are pharmacists working alone in a shift and phar-
macists working with a pharmaceutical technician. The results indicate that
socio-demographic factors and exposure to professional stress lead to job burnout",
publisher = "Elsevier Science Inc",
journal = "Value in Health",
title = "Job burnout predictors in community pharmacists in Serbia",
volume = "19",
number = "7, 7",
pages = "A475",
doi = "10.1016/j.jval.2016.09.746"
}

Jocić, D. D., Krajnović, D.,& Lakić, D.. (2016). Job burnout predictors in community pharmacists in Serbia. in Value in Health
Elsevier Science Inc., 19(7), A475.
https://doi.org/10.1016/j.jval.2016.09.746

Jocić DD, Krajnović D, Lakić D. Job burnout predictors in community pharmacists in Serbia. in Value in Health. 2016;19(7):A475.
doi:10.1016/j.jval.2016.09.746 .

Jocić, D. D., Krajnović, Dušanka, Lakić, Dragana, "Job burnout predictors in community pharmacists in Serbia" in Value in Health, 19, no. 7 (2016):A475,
https://doi.org/10.1016/j.jval.2016.09.746 . .

TY  - JOUR
AU  - Stojković, Tatjana
AU  - Marinković, Valentina
AU  - Lakić, Dragana
AU  - Bogavac-Stanojević, Nataša
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2747
AB  - It has been determined that Pharmacist-Managed Anticoagulation Service (PMAS) for patients on warfarin improves anticoagulation control and decreases the rate of bleeding, thus reducing the overall health care costs. This study aims to compare the cost-effectiveness of providing pharmaceutical care (PC) and usual medical care (UMC) to patients on warfarin, from the perspective of the National Health Insurance Fund (NHIF) in Serbia. The cost-effectiveness analysis was conducted, with a time horizon of 10 days. Decision tree modeling combined data on efficacy from eligible studies, while the costs were taken from NHIF Drug and Service fee lists. Additionally, the budget impact analysis was performed, aiming to project annual savings by implementing PMAS as a part of anticoagulation clinics. PC has been perceived to be cost-effective strategy, since it enables a higher probability of well controlled INR value (additional effectiveness 0,154), along with lower costs (-374,51 RSD), compared to UMC. Negative incremental cost-effectiveness ratio additionally demonstrated cost-effectiveness of PC, as dominant strategy. Sensitivity analysis confirmed the model robustness, and budget impact analysis has also demonstrated significant annual savings, in the total amount of 50.863.313 RSD for a five year period 2016-2020. Providing PC to patients on warfarin represents a more cost-efficient strategy than UMS, in addition to better safety profile, which is why it should be implemented in the national health care system in the future.
AB  - Utvrđeno je da sprovođenje menadžmenta terapije varfarinom od strane farmaceuta značajno unapređuje kontrolu antikoagulacije i smanjuje broj slučajeva krvarenja, a time i pridružene troškove lečenja. Cilj ovog rada je farmakoekonomska evaluacija pružanja farmaceutske zdravstvene zaštite (FZZ) pacijentima na varfarinu u odnosu na standardnu zdravstvenu zaštitu (SZZ), iz perspektive Republičkog fonda za zdravstveno osiguranje (RFZO). Sprovedena je analiza isplativosti primenom drveta odlučivanja, za period od 10 dana. U modelu su kombinovani podaci za posmatrane ishode iz odgovarajućih studija, dok su direktni medicinski troškovi preuzeti iz važećih cenovnika zdravstvenih usluga, kao i Liste lekova RFZO. Dodatno je sprovedena analiza uticaja na budžet, radi projektovanja potencijalnih ušteda u slučaju implementacije ove farmaceutske usluge. FZZ je troškovno isplativija strategija, obzirom na veću efektivnost (+0,154), a manji trošak (-374,51 RSD) u odnosu na SZZ. Negativna vrednost inkrementalnog odnosa troškova i efektivnosti za FZZ dodatno potvrđuje njenu isplativost, kao dominantne strategije. Analiza osetljivosti je potvrdila robusnost modela, dok su analizom uticaja na budžet projektovane značajne uštede, od 50.863.313 RSD za petogodišnji period 2016.-2020. Pružanje FZZ pacijentima na antikoagulantnoj terapiji varfarinom predstavlja troškovno-isplativiju strategiju u odnosu na SZZ u Republici Srbiji, zbog čega je poželjno da se implementira u nacionalni zdravstveni sistem u budućnosti.
PB  - Savez farmaceutskih udruženja Srbije, Beograd
T2  - Arhiv za farmaciju
T1  - Pharmacoeconomic evaluation of providing pharmacist-managed anticoagulation service to patients on warfarin
T1  - Farmakoekonomska evaluacija pružanja farmaceutske usluge pacijentima na antikoagulantnoj terapiji varfarinom
VL  - 66
IS  - 2
SP  - 103
EP  - 117
DO  - 10.5937/arhfarm1602103S
ER  - 

@article{
author = "Stojković, Tatjana and Marinković, Valentina and Lakić, Dragana and Bogavac-Stanojević, Nataša",
year = "2016",
abstract = "It has been determined that Pharmacist-Managed Anticoagulation Service (PMAS) for patients on warfarin improves anticoagulation control and decreases the rate of bleeding, thus reducing the overall health care costs. This study aims to compare the cost-effectiveness of providing pharmaceutical care (PC) and usual medical care (UMC) to patients on warfarin, from the perspective of the National Health Insurance Fund (NHIF) in Serbia. The cost-effectiveness analysis was conducted, with a time horizon of 10 days. Decision tree modeling combined data on efficacy from eligible studies, while the costs were taken from NHIF Drug and Service fee lists. Additionally, the budget impact analysis was performed, aiming to project annual savings by implementing PMAS as a part of anticoagulation clinics. PC has been perceived to be cost-effective strategy, since it enables a higher probability of well controlled INR value (additional effectiveness 0,154), along with lower costs (-374,51 RSD), compared to UMC. Negative incremental cost-effectiveness ratio additionally demonstrated cost-effectiveness of PC, as dominant strategy. Sensitivity analysis confirmed the model robustness, and budget impact analysis has also demonstrated significant annual savings, in the total amount of 50.863.313 RSD for a five year period 2016-2020. Providing PC to patients on warfarin represents a more cost-efficient strategy than UMS, in addition to better safety profile, which is why it should be implemented in the national health care system in the future., Utvrđeno je da sprovođenje menadžmenta terapije varfarinom od strane farmaceuta značajno unapređuje kontrolu antikoagulacije i smanjuje broj slučajeva krvarenja, a time i pridružene troškove lečenja. Cilj ovog rada je farmakoekonomska evaluacija pružanja farmaceutske zdravstvene zaštite (FZZ) pacijentima na varfarinu u odnosu na standardnu zdravstvenu zaštitu (SZZ), iz perspektive Republičkog fonda za zdravstveno osiguranje (RFZO). Sprovedena je analiza isplativosti primenom drveta odlučivanja, za period od 10 dana. U modelu su kombinovani podaci za posmatrane ishode iz odgovarajućih studija, dok su direktni medicinski troškovi preuzeti iz važećih cenovnika zdravstvenih usluga, kao i Liste lekova RFZO. Dodatno je sprovedena analiza uticaja na budžet, radi projektovanja potencijalnih ušteda u slučaju implementacije ove farmaceutske usluge. FZZ je troškovno isplativija strategija, obzirom na veću efektivnost (+0,154), a manji trošak (-374,51 RSD) u odnosu na SZZ. Negativna vrednost inkrementalnog odnosa troškova i efektivnosti za FZZ dodatno potvrđuje njenu isplativost, kao dominantne strategije. Analiza osetljivosti je potvrdila robusnost modela, dok su analizom uticaja na budžet projektovane značajne uštede, od 50.863.313 RSD za petogodišnji period 2016.-2020. Pružanje FZZ pacijentima na antikoagulantnoj terapiji varfarinom predstavlja troškovno-isplativiju strategiju u odnosu na SZZ u Republici Srbiji, zbog čega je poželjno da se implementira u nacionalni zdravstveni sistem u budućnosti.",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "Pharmacoeconomic evaluation of providing pharmacist-managed anticoagulation service to patients on warfarin, Farmakoekonomska evaluacija pružanja farmaceutske usluge pacijentima na antikoagulantnoj terapiji varfarinom",
volume = "66",
number = "2",
pages = "103-117",
doi = "10.5937/arhfarm1602103S"
}

Stojković, T., Marinković, V., Lakić, D.,& Bogavac-Stanojević, N.. (2016). Pharmacoeconomic evaluation of providing pharmacist-managed anticoagulation service to patients on warfarin. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 66(2), 103-117.
https://doi.org/10.5937/arhfarm1602103S

Stojković T, Marinković V, Lakić D, Bogavac-Stanojević N. Pharmacoeconomic evaluation of providing pharmacist-managed anticoagulation service to patients on warfarin. in Arhiv za farmaciju. 2016;66(2):103-117.
doi:10.5937/arhfarm1602103S .

Stojković, Tatjana, Marinković, Valentina, Lakić, Dragana, Bogavac-Stanojević, Nataša, "Pharmacoeconomic evaluation of providing pharmacist-managed anticoagulation service to patients on warfarin" in Arhiv za farmaciju, 66, no. 2 (2016):103-117,
https://doi.org/10.5937/arhfarm1602103S . .

TY  - JOUR
AU  - Petrova, Guenka
AU  - Benbassat, Boriana
AU  - Lakić, Dragana
AU  - Dimitrova, Maria
AU  - Mitov, Konstantin
AU  - Dimitrov, Josif
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2551
AB  - The aim of this study was to explore the cost-effectiveness of short protocols including different types of gonadotropins for controlled ovarian hyperstimulation (COH) for in vitro fertilization (IVF). A retrospective, observational study of the real-life practice in a specialized IVF gynaecology clinic in 2009-2013 was carried out. All women on short COH protocols were recruited into three groups: COH including recombinant follicle stimulating hormone (rFSH) and urinary-FSH (urFSH) (n = 173); including urFSH alone (n = 289); and including rFSH alone (n = 212). The cost-effectiveness of the COH protocols was explored in two different case scenarios for possible outcomes. The first case scenario took into consideration a successful live birth, and the second one, the women to achieve pregnancy with live birth. Decision modelling was done using the TreeAge 2014 Software. According to the results in the first case scenario, the rFSH plus urFSH COH approach showed the highest weighted probability (p = 0.38) of live birth, but the urFSH alternative was cost-effective. The results in the second case scenario demonstrated that the urFSH protocol was again the cost-effective alternative. These results suggest that the strategy with urFSH should be preferred in both cases, but rFSH could also be considered as a cost-effective alternative for successful live birth and achieving pregnancy and delivery, since the incremental cost-effectiveness ratio in comparison with the urFSH protocol is below the gross domestic product per capita. The combined approach of rFSH and urFSH was shown not to be cost-effective in both explored scenarios.
PB  - Taylor & Francis Ltd, Abingdon
T2  - Biotechnology & Biotechnological Equipment
T1  - Cost-effectiveness of short COH protocols with GnRH antagonists using different types of gonadotropins for in vitro fertilization
VL  - 30
IS  - 3
SP  - 614
EP  - 621
DO  - 10.1080/13102818.2016.1160796
ER  - 

@article{
author = "Petrova, Guenka and Benbassat, Boriana and Lakić, Dragana and Dimitrova, Maria and Mitov, Konstantin and Dimitrov, Josif",
year = "2016",
abstract = "The aim of this study was to explore the cost-effectiveness of short protocols including different types of gonadotropins for controlled ovarian hyperstimulation (COH) for in vitro fertilization (IVF). A retrospective, observational study of the real-life practice in a specialized IVF gynaecology clinic in 2009-2013 was carried out. All women on short COH protocols were recruited into three groups: COH including recombinant follicle stimulating hormone (rFSH) and urinary-FSH (urFSH) (n = 173); including urFSH alone (n = 289); and including rFSH alone (n = 212). The cost-effectiveness of the COH protocols was explored in two different case scenarios for possible outcomes. The first case scenario took into consideration a successful live birth, and the second one, the women to achieve pregnancy with live birth. Decision modelling was done using the TreeAge 2014 Software. According to the results in the first case scenario, the rFSH plus urFSH COH approach showed the highest weighted probability (p = 0.38) of live birth, but the urFSH alternative was cost-effective. The results in the second case scenario demonstrated that the urFSH protocol was again the cost-effective alternative. These results suggest that the strategy with urFSH should be preferred in both cases, but rFSH could also be considered as a cost-effective alternative for successful live birth and achieving pregnancy and delivery, since the incremental cost-effectiveness ratio in comparison with the urFSH protocol is below the gross domestic product per capita. The combined approach of rFSH and urFSH was shown not to be cost-effective in both explored scenarios.",
publisher = "Taylor & Francis Ltd, Abingdon",
journal = "Biotechnology & Biotechnological Equipment",
title = "Cost-effectiveness of short COH protocols with GnRH antagonists using different types of gonadotropins for in vitro fertilization",
volume = "30",
number = "3",
pages = "614-621",
doi = "10.1080/13102818.2016.1160796"
}

Petrova, G., Benbassat, B., Lakić, D., Dimitrova, M., Mitov, K.,& Dimitrov, J.. (2016). Cost-effectiveness of short COH protocols with GnRH antagonists using different types of gonadotropins for in vitro fertilization. in Biotechnology & Biotechnological Equipment
Taylor & Francis Ltd, Abingdon., 30(3), 614-621.
https://doi.org/10.1080/13102818.2016.1160796

Petrova G, Benbassat B, Lakić D, Dimitrova M, Mitov K, Dimitrov J. Cost-effectiveness of short COH protocols with GnRH antagonists using different types of gonadotropins for in vitro fertilization. in Biotechnology & Biotechnological Equipment. 2016;30(3):614-621.
doi:10.1080/13102818.2016.1160796 .

Petrova, Guenka, Benbassat, Boriana, Lakić, Dragana, Dimitrova, Maria, Mitov, Konstantin, Dimitrov, Josif, "Cost-effectiveness of short COH protocols with GnRH antagonists using different types of gonadotropins for in vitro fertilization" in Biotechnology & Biotechnological Equipment, 30, no. 3 (2016):614-621,
https://doi.org/10.1080/13102818.2016.1160796 . .

TY  - JOUR
AU  - Bogavac-Stanojević, Nataša
AU  - Lakić, Dragana
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2624
AB  - Major depressive disorder (MDD) is a major psychiatric illness and it is predicted to be the second leading cause of disability by 2020 with a lifetime prevalence of about 13%. Selective serotonin reuptake inhibitors (SSRIs) are the most commonly used therapeutic class for MDD. However, response to SSRI treatment varies considerably between patients. Biomarkers of treatment response may enable clinicians to target the appropriate drug for each patient. Biomarkers need to have accuracy in real life, sensitivity, specificity, and relevance to depression. Introduction of MDD biomarkers into the health care system can increase the overall cost of clinical diagnosis of patients. Because of that, decisions to allocate health research funding must be based on drug effectiveness and cost-effectiveness. The assessment of MDD biomarkers should include reliable evidence of associated drug effectiveness, adverse events and consequences (reduced productivity and quality of life, disability) and effectiveness of alternative approaches, other drug classes or behavioral or alternative therapies. In addition, all the variables included in an economic model (probabilities, outcomes, and costs) should be based on reliable evidence gained from the literatureideally meta-analysesand the evidence should also be determined by informed and specific expert opinion. Early assessment can guide decisions about whether or not to continue test development, and ideally to optimize the process. Drug Dev Res 77 : 374-378, 2016.
PB  - Wiley, Hoboken
T2  - Drug Development Research
T1  - Biomarkers for Major Depressive Disorder: Economic Considerations
VL  - 77
IS  - 7
SP  - 374
EP  - 378
DO  - 10.1002/ddr.21330
ER  - 

@article{
author = "Bogavac-Stanojević, Nataša and Lakić, Dragana",
year = "2016",
abstract = "Major depressive disorder (MDD) is a major psychiatric illness and it is predicted to be the second leading cause of disability by 2020 with a lifetime prevalence of about 13%. Selective serotonin reuptake inhibitors (SSRIs) are the most commonly used therapeutic class for MDD. However, response to SSRI treatment varies considerably between patients. Biomarkers of treatment response may enable clinicians to target the appropriate drug for each patient. Biomarkers need to have accuracy in real life, sensitivity, specificity, and relevance to depression. Introduction of MDD biomarkers into the health care system can increase the overall cost of clinical diagnosis of patients. Because of that, decisions to allocate health research funding must be based on drug effectiveness and cost-effectiveness. The assessment of MDD biomarkers should include reliable evidence of associated drug effectiveness, adverse events and consequences (reduced productivity and quality of life, disability) and effectiveness of alternative approaches, other drug classes or behavioral or alternative therapies. In addition, all the variables included in an economic model (probabilities, outcomes, and costs) should be based on reliable evidence gained from the literatureideally meta-analysesand the evidence should also be determined by informed and specific expert opinion. Early assessment can guide decisions about whether or not to continue test development, and ideally to optimize the process. Drug Dev Res 77 : 374-378, 2016.",
publisher = "Wiley, Hoboken",
journal = "Drug Development Research",
title = "Biomarkers for Major Depressive Disorder: Economic Considerations",
volume = "77",
number = "7",
pages = "374-378",
doi = "10.1002/ddr.21330"
}

Bogavac-Stanojević, N.,& Lakić, D.. (2016). Biomarkers for Major Depressive Disorder: Economic Considerations. in Drug Development Research
Wiley, Hoboken., 77(7), 374-378.
https://doi.org/10.1002/ddr.21330

Bogavac-Stanojević N, Lakić D. Biomarkers for Major Depressive Disorder: Economic Considerations. in Drug Development Research. 2016;77(7):374-378.
doi:10.1002/ddr.21330 .

Bogavac-Stanojević, Nataša, Lakić, Dragana, "Biomarkers for Major Depressive Disorder: Economic Considerations" in Drug Development Research, 77, no. 7 (2016):374-378,
https://doi.org/10.1002/ddr.21330 . .

TY  - JOUR
AU  - Petrović, Stanislava
AU  - Bogavac-Stanojević, Nataša
AU  - Lakić, Dragana
AU  - Peco-Antić, Amira
AU  - Vulicević, Irena
AU  - Ivanišević, Ivana
AU  - Kotur-Stevuljević, Jelena
AU  - Jelić-Ivanović, Zorana
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2467
AB  - Introduction: Acute kidney injury (AKI) is significant problem in children with congenital heart disease (CHD) who undergo cardiac surgery. The economic impact of a biomarker-based diagnostic strategy for AKI in pediatric populations undergoing CHD surgery is unknown. The aim of this study was to perform the cost effectiveness analysis of using serum cystatin C (sCysC), urine neutrophil gelatinase-associated lipocalin (uNGAL) and urine liver fatty acid-binding protein (uL-FABP) for the diagnosis of AKI in children after cardiac surgery compared with current diagnostic method (monitoring of serum creatinine (sCr) level). Materials and methods: We developed a decision analytical model to estimate incremental cost-effectiveness of different biomarker-based diagnostic strategies compared to current diagnostic strategy. The Markov model was created to compare the lifetime cost associated with using of sCysC, uNGAL, uL-FABP with monitoring of sCr level for the diagnosis of AKI. The utility measurement included in the analysis was quality-adjusted life years (QALY). The results of the analysis are presented as the incremental cost-effectiveness ratio (ICER). Results: Analysed biomarker-based diagnostic strategies for AKI were cost-effective compared to current diagnostic method. However, uNGAL and sCys C strategies yielded higher costs and lower effectiveness compared to uL-FABP strategy. uL-FABP added 1.43 QALY compared to current diagnostic method at an additional cost of $8521.87 per patient. Therefore, ICER for uL-FABP compared to sCr was $5959.35/QALY. Conclusions: Our results suggest that the use of uL-FABP would represent cost effective strategy for early diagnosis of AKI in children after cardiac surgery.
PB  - Croatian Soc Medical Biochemists, Zagreb
T2  - Biochemia Medica
T1  - Cost-effectiveness analysis of acute kidney injury biomarkers in pediatric cardiac surgery
VL  - 25
IS  - 2
SP  - 262
EP  - 271
DO  - 10.11613/BM.2015.027
ER  - 

@article{
author = "Petrović, Stanislava and Bogavac-Stanojević, Nataša and Lakić, Dragana and Peco-Antić, Amira and Vulicević, Irena and Ivanišević, Ivana and Kotur-Stevuljević, Jelena and Jelić-Ivanović, Zorana",
year = "2015",
abstract = "Introduction: Acute kidney injury (AKI) is significant problem in children with congenital heart disease (CHD) who undergo cardiac surgery. The economic impact of a biomarker-based diagnostic strategy for AKI in pediatric populations undergoing CHD surgery is unknown. The aim of this study was to perform the cost effectiveness analysis of using serum cystatin C (sCysC), urine neutrophil gelatinase-associated lipocalin (uNGAL) and urine liver fatty acid-binding protein (uL-FABP) for the diagnosis of AKI in children after cardiac surgery compared with current diagnostic method (monitoring of serum creatinine (sCr) level). Materials and methods: We developed a decision analytical model to estimate incremental cost-effectiveness of different biomarker-based diagnostic strategies compared to current diagnostic strategy. The Markov model was created to compare the lifetime cost associated with using of sCysC, uNGAL, uL-FABP with monitoring of sCr level for the diagnosis of AKI. The utility measurement included in the analysis was quality-adjusted life years (QALY). The results of the analysis are presented as the incremental cost-effectiveness ratio (ICER). Results: Analysed biomarker-based diagnostic strategies for AKI were cost-effective compared to current diagnostic method. However, uNGAL and sCys C strategies yielded higher costs and lower effectiveness compared to uL-FABP strategy. uL-FABP added 1.43 QALY compared to current diagnostic method at an additional cost of $8521.87 per patient. Therefore, ICER for uL-FABP compared to sCr was $5959.35/QALY. Conclusions: Our results suggest that the use of uL-FABP would represent cost effective strategy for early diagnosis of AKI in children after cardiac surgery.",
publisher = "Croatian Soc Medical Biochemists, Zagreb",
journal = "Biochemia Medica",
title = "Cost-effectiveness analysis of acute kidney injury biomarkers in pediatric cardiac surgery",
volume = "25",
number = "2",
pages = "262-271",
doi = "10.11613/BM.2015.027"
}

Petrović, S., Bogavac-Stanojević, N., Lakić, D., Peco-Antić, A., Vulicević, I., Ivanišević, I., Kotur-Stevuljević, J.,& Jelić-Ivanović, Z.. (2015). Cost-effectiveness analysis of acute kidney injury biomarkers in pediatric cardiac surgery. in Biochemia Medica
Croatian Soc Medical Biochemists, Zagreb., 25(2), 262-271.
https://doi.org/10.11613/BM.2015.027

Petrović S, Bogavac-Stanojević N, Lakić D, Peco-Antić A, Vulicević I, Ivanišević I, Kotur-Stevuljević J, Jelić-Ivanović Z. Cost-effectiveness analysis of acute kidney injury biomarkers in pediatric cardiac surgery. in Biochemia Medica. 2015;25(2):262-271.
doi:10.11613/BM.2015.027 .

Petrović, Stanislava, Bogavac-Stanojević, Nataša, Lakić, Dragana, Peco-Antić, Amira, Vulicević, Irena, Ivanišević, Ivana, Kotur-Stevuljević, Jelena, Jelić-Ivanović, Zorana, "Cost-effectiveness analysis of acute kidney injury biomarkers in pediatric cardiac surgery" in Biochemia Medica, 25, no. 2 (2015):262-271,
https://doi.org/10.11613/BM.2015.027 . .

TY  - JOUR
AU  - Odalović, Marina
AU  - Tadić, Ivana
AU  - Lakić, Dragana
AU  - Nordeng, Hedvig
AU  - Lupattelli, Angela
AU  - Tasić, Ljiljana
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2319
AB  - Background: The Edinburgh Postnatal Depression Scale (EPDS) is well accepted for detecting symptoms of postnatal depression. The aim of this study was to examine psychometric properties and to evaluate structural models of the Serbian translation of EPDS in pregnant and postpartum women. Methods: The original English version of the EPDS was translated into Serbian, and checked by means of back-translation. Data were collected via an anonymous online questionnaire posted on a Serbian website devoted to pregnancy topics. The study sample included 201 women (76 pregnant, 125 postpartum). The internal consistency of the scale was measured by Cronbach's a coefficient. Principal component analysis was used to determine scale dimensions while confirmatory factor analysis was used to evaluate model fit. Findings: Cronbach a coefficient was 0.84 and 0.83 in pregnant and postpartum women, respectively, which indicated good internal consistency of the Serbian EPDS. Three dimensions of the scale were revealed in both groups of women. Goodness of fit indices described good and excellent model in pregnant and postpartum women, respectively. High level of depression symptoms (score > 13) was recorded in 27.6% and 24.8% (p > 0.05) of pregnant and postpartum women, respectively. Moderate level of depression symptoms (score 10-12) was recorded in 21.1% and 16.8% (p > 0.05) of pregnant and postpartum women, respectively. Conclusion: The Serbian translation of the EPDS showed good consistency and good model characteristics in pregnant and postpartum women. However, cut-off values, sensitivity and specificity of the scale should be determined in the further studies with more representative samples of women.
PB  - Elsevier BV
T2  - World Journal of Gastroenterology
T1  - Translation and factor analysis of structural models of Edinburgh Postnatal Depression Scale in Serbian pregnant and postpartum women - Web-based study
VL  - 28
IS  - 3
DO  - 10.1016/j.wombi.2015.01.014
ER  - 

@article{
author = "Odalović, Marina and Tadić, Ivana and Lakić, Dragana and Nordeng, Hedvig and Lupattelli, Angela and Tasić, Ljiljana",
year = "2015",
abstract = "Background: The Edinburgh Postnatal Depression Scale (EPDS) is well accepted for detecting symptoms of postnatal depression. The aim of this study was to examine psychometric properties and to evaluate structural models of the Serbian translation of EPDS in pregnant and postpartum women. Methods: The original English version of the EPDS was translated into Serbian, and checked by means of back-translation. Data were collected via an anonymous online questionnaire posted on a Serbian website devoted to pregnancy topics. The study sample included 201 women (76 pregnant, 125 postpartum). The internal consistency of the scale was measured by Cronbach's a coefficient. Principal component analysis was used to determine scale dimensions while confirmatory factor analysis was used to evaluate model fit. Findings: Cronbach a coefficient was 0.84 and 0.83 in pregnant and postpartum women, respectively, which indicated good internal consistency of the Serbian EPDS. Three dimensions of the scale were revealed in both groups of women. Goodness of fit indices described good and excellent model in pregnant and postpartum women, respectively. High level of depression symptoms (score > 13) was recorded in 27.6% and 24.8% (p > 0.05) of pregnant and postpartum women, respectively. Moderate level of depression symptoms (score 10-12) was recorded in 21.1% and 16.8% (p > 0.05) of pregnant and postpartum women, respectively. Conclusion: The Serbian translation of the EPDS showed good consistency and good model characteristics in pregnant and postpartum women. However, cut-off values, sensitivity and specificity of the scale should be determined in the further studies with more representative samples of women.",
publisher = "Elsevier BV",
journal = "World Journal of Gastroenterology",
title = "Translation and factor analysis of structural models of Edinburgh Postnatal Depression Scale in Serbian pregnant and postpartum women - Web-based study",
volume = "28",
number = "3",
doi = "10.1016/j.wombi.2015.01.014"
}

Odalović, M., Tadić, I., Lakić, D., Nordeng, H., Lupattelli, A.,& Tasić, L.. (2015). Translation and factor analysis of structural models of Edinburgh Postnatal Depression Scale in Serbian pregnant and postpartum women - Web-based study. in World Journal of Gastroenterology
Elsevier BV., 28(3).
https://doi.org/10.1016/j.wombi.2015.01.014

Odalović M, Tadić I, Lakić D, Nordeng H, Lupattelli A, Tasić L. Translation and factor analysis of structural models of Edinburgh Postnatal Depression Scale in Serbian pregnant and postpartum women - Web-based study. in World Journal of Gastroenterology. 2015;28(3).
doi:10.1016/j.wombi.2015.01.014 .

Odalović, Marina, Tadić, Ivana, Lakić, Dragana, Nordeng, Hedvig, Lupattelli, Angela, Tasić, Ljiljana, "Translation and factor analysis of structural models of Edinburgh Postnatal Depression Scale in Serbian pregnant and postpartum women - Web-based study" in World Journal of Gastroenterology, 28, no. 3 (2015),
https://doi.org/10.1016/j.wombi.2015.01.014 . .

TY  - JOUR
AU  - Živković, Marija
AU  - Lakić, Dragana
AU  - Tadić, Ivana
AU  - Odalović, Marina
AU  - Bogavac-Stanojević, Nataša
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2523
AB  - Empirical application of antifungal drugs in the treatment of invasive fungal infections (IFI) in febrile neutropenia represent significant cost, but it is essential in patients with leukemia and after hematopoietic stem cell transplantation. Numerous clinical studies have shown little difference in the efficacy of amphotericin B and caspofungin in IFI empirical therapy, but it does not reflect their cost-effectiveness. The aim of this study was to compare the costeffectiveness of caspofungin and amphotericin B lipid complex (ABLC) in the empirical antifungal therapy in patients with febrile neutropenia using model-decision tree, from the perspective of the National Health Insurance Fund (NHIF). We used the cost-effectiveness analysis, for a period of 14 days of therapy. In model we combined data on efficacy from randomized clinical trials, while the costs were taken from the Drug list or service fee NHIF. The total cost per additional cured fungal infection with caspofungin was 639,750.06 RSD, while with ABLC was 2,153,403.61 RSD. In the sensitivity analysis, using different weights of patients (50kg or 70kg) and different doses of ABLC, caspofungin was again most cost-effective strategy for empirical antifungal therapy. Caspofungin, in addition to a better safety profile, is more cost-efficient than ABLC. This fact should be kept in mind when choosing a therapy for the treatment of IFI in patients with febrile neutropenia.
AB  - Empirijska primena antimikotika u terapiji invazivnih gljivičnih infekcija (IGI) u febrilnoj neutropeniji predstavlja značajan trošak, ali je neophodna kod pacijenata sa leukemijom i nakon transplantacije matičnih ćelija hematopoeze. Brojne kliničke studije pokazale su male razlike u efikasnosti amfotericina B i kaspofungina u empirijskoj terapiji IGI, ali to ne oslikava u pravoj meri odnos trošak-efektivnost. Cilj rada je bio poređenje isplativosti kaspofungina i amfotericina B lipidni kompleks (ABLC) u empirijskoj antigljivičnoj terapiji kod pacijenata sa febrilnom neutropenijom kroz model-drvo odlučivanja, a iz perspektive Republičkog fonda za zdravstveno osiguranje (RFZO). Primenjena je analiza isplativosti, (cost-effectiveness analsys - CEA), za period od 14 dana terapije. U modelu su kombinovani podaci o efikasnosti iz randomizovanih kliničkih studija, dok su troškovi uzeti iz važećeg cenovnika zdravstvenih usluga i Liste lekova RFZO. Ukupan trošak po dodatno izlečenoj gljivičnoj infekciji za kaspofungin iznosi 639.750,06 RSD, dok je za ABLC 2.153.403,61 RSD. U analizi osetljivosti, primenom različite telesne težine pacijenata (50kg ili 70kg) i različite doze ABLC, kaspofungin je ponovo bio isplativija strategija empirijske antigljivične terapije. Kaspofungin, pored boljeg bezbednosnog profila je i troškovno isplativiji od ABLC. Ovu činjenicu bi trebalo imati u vidu prilikom odabira terapije za lečenje IGI kod pacijenata sa febrilnom neutropenijom.
PB  - Savez farmaceutskih udruženja Srbije, Beograd
T2  - Arhiv za farmaciju
T1  - A pharmacoeconomic evaluation of capsofungin and amphotericin B for intravenous infusion for treatment of systemic fungal infection
T1  - Farmakoekonomska evaluacija primene rastvora za infuziju kaspofungina i amfotericina B u terapiji teških sistemskih mikoza
VL  - 65
IS  - 1
SP  - 33
EP  - 46
DO  - 10.5937/arhfarm1501033Z
ER  - 

@article{
author = "Živković, Marija and Lakić, Dragana and Tadić, Ivana and Odalović, Marina and Bogavac-Stanojević, Nataša",
year = "2015",
abstract = "Empirical application of antifungal drugs in the treatment of invasive fungal infections (IFI) in febrile neutropenia represent significant cost, but it is essential in patients with leukemia and after hematopoietic stem cell transplantation. Numerous clinical studies have shown little difference in the efficacy of amphotericin B and caspofungin in IFI empirical therapy, but it does not reflect their cost-effectiveness. The aim of this study was to compare the costeffectiveness of caspofungin and amphotericin B lipid complex (ABLC) in the empirical antifungal therapy in patients with febrile neutropenia using model-decision tree, from the perspective of the National Health Insurance Fund (NHIF). We used the cost-effectiveness analysis, for a period of 14 days of therapy. In model we combined data on efficacy from randomized clinical trials, while the costs were taken from the Drug list or service fee NHIF. The total cost per additional cured fungal infection with caspofungin was 639,750.06 RSD, while with ABLC was 2,153,403.61 RSD. In the sensitivity analysis, using different weights of patients (50kg or 70kg) and different doses of ABLC, caspofungin was again most cost-effective strategy for empirical antifungal therapy. Caspofungin, in addition to a better safety profile, is more cost-efficient than ABLC. This fact should be kept in mind when choosing a therapy for the treatment of IFI in patients with febrile neutropenia., Empirijska primena antimikotika u terapiji invazivnih gljivičnih infekcija (IGI) u febrilnoj neutropeniji predstavlja značajan trošak, ali je neophodna kod pacijenata sa leukemijom i nakon transplantacije matičnih ćelija hematopoeze. Brojne kliničke studije pokazale su male razlike u efikasnosti amfotericina B i kaspofungina u empirijskoj terapiji IGI, ali to ne oslikava u pravoj meri odnos trošak-efektivnost. Cilj rada je bio poređenje isplativosti kaspofungina i amfotericina B lipidni kompleks (ABLC) u empirijskoj antigljivičnoj terapiji kod pacijenata sa febrilnom neutropenijom kroz model-drvo odlučivanja, a iz perspektive Republičkog fonda za zdravstveno osiguranje (RFZO). Primenjena je analiza isplativosti, (cost-effectiveness analsys - CEA), za period od 14 dana terapije. U modelu su kombinovani podaci o efikasnosti iz randomizovanih kliničkih studija, dok su troškovi uzeti iz važećeg cenovnika zdravstvenih usluga i Liste lekova RFZO. Ukupan trošak po dodatno izlečenoj gljivičnoj infekciji za kaspofungin iznosi 639.750,06 RSD, dok je za ABLC 2.153.403,61 RSD. U analizi osetljivosti, primenom različite telesne težine pacijenata (50kg ili 70kg) i različite doze ABLC, kaspofungin je ponovo bio isplativija strategija empirijske antigljivične terapije. Kaspofungin, pored boljeg bezbednosnog profila je i troškovno isplativiji od ABLC. Ovu činjenicu bi trebalo imati u vidu prilikom odabira terapije za lečenje IGI kod pacijenata sa febrilnom neutropenijom.",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "A pharmacoeconomic evaluation of capsofungin and amphotericin B for intravenous infusion for treatment of systemic fungal infection, Farmakoekonomska evaluacija primene rastvora za infuziju kaspofungina i amfotericina B u terapiji teških sistemskih mikoza",
volume = "65",
number = "1",
pages = "33-46",
doi = "10.5937/arhfarm1501033Z"
}

Živković, M., Lakić, D., Tadić, I., Odalović, M.,& Bogavac-Stanojević, N.. (2015). A pharmacoeconomic evaluation of capsofungin and amphotericin B for intravenous infusion for treatment of systemic fungal infection. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 65(1), 33-46.
https://doi.org/10.5937/arhfarm1501033Z

Živković M, Lakić D, Tadić I, Odalović M, Bogavac-Stanojević N. A pharmacoeconomic evaluation of capsofungin and amphotericin B for intravenous infusion for treatment of systemic fungal infection. in Arhiv za farmaciju. 2015;65(1):33-46.
doi:10.5937/arhfarm1501033Z .

Živković, Marija, Lakić, Dragana, Tadić, Ivana, Odalović, Marina, Bogavac-Stanojević, Nataša, "A pharmacoeconomic evaluation of capsofungin and amphotericin B for intravenous infusion for treatment of systemic fungal infection" in Arhiv za farmaciju, 65, no. 1 (2015):33-46,
https://doi.org/10.5937/arhfarm1501033Z . .

TY  - JOUR
AU  - Lakić, Dragana
AU  - Tadić, Ivana
AU  - Odalović, Marina
AU  - Kolundžić, Svetlana
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2522
AB  - Urinary tract infections are inflammations processes on lower or upper parts of urinary tract. Therapy of urinary tract infections differs for complicated and non-complicated infections and site of infection. The aim of this paper is pharmacoeconomic analysis of different strategies in management of urinary tract infections from the perspective of Republic Fond for Health Insurance. The decision tree was constructed to evaluate costs and effectiveness of different strategies used for treatment of non-pregnant, adult women. As a positive outcome of the treatment number of cases where simptoms disapered is used. The results implied that the least costly strategy available is empiric treatment. More expensive but with greater outcomes was the strategy involving laboratory test together with empiric treatment. Although the empiric treatment proved to be cost-effective and in accordance with current recommendations and guidelines for therapy, recognition of the impact of this strategy upon antibiotic resistance may lead to conclusion that the dipstick strategy is superior strategy.
AB  - Infekcije urinarnog trakta zahvataju donje i gornje delove urinarnog trakta. Terapija infekcija se razlikuje u zavisnosti da li su u pitanju komplikovane ili nekomplikovane infekcije kao i od mesta infekcije. Cilj ovog rada je farmakoekonomska analiza isplativosti primene različitih strategija u lečenju infekcija urinarnog trakta iz perspektive Republičkog fonda za zdravstveno osiguranje. Zarad procene troškova i efikasnosti primene različitih strategija u lečenju infekcija urinarnog trakta u odraslih žena koje nisu trudne konstruisano je drvo odlučivanja. Kao ishod lečenja posmatran je broj slučajeva u kojima je došlo do prestanka simptoma. Rezultati istraživanja su pokazali da je najisplativija strategija empirijska primena antibiotika. Nešto skuplja i efikasnija strategija je primena laboratorijskih testova uz empirijsku primenu antibiotika. Iako je empirijska primena antibiotika troškovno isplativa i u skladu sa važećim preporukama i protokolima lečenja infekcije urinarnog trakta, ukoliko se razmotri i antibiotska rezistencija kao rastući zdravstveni problem, strategija primene dipstik testa može biti superiorna.
PB  - Savez farmaceutskih udruženja Srbije, Beograd
T2  - Arhiv za farmaciju
T1  - Antibacterial therapy of the urinary tract infections: Pharmacoeconomic aspect
T1  - Upotreba antibakterijskih lekova u lečenju infekcija urinarnog trakta - farmakoekonomski aspect
VL  - 65
IS  - 1
SP  - 47
EP  - 57
DO  - 10.5937/arhfarm1501047L
ER  - 

@article{
author = "Lakić, Dragana and Tadić, Ivana and Odalović, Marina and Kolundžić, Svetlana",
year = "2015",
abstract = "Urinary tract infections are inflammations processes on lower or upper parts of urinary tract. Therapy of urinary tract infections differs for complicated and non-complicated infections and site of infection. The aim of this paper is pharmacoeconomic analysis of different strategies in management of urinary tract infections from the perspective of Republic Fond for Health Insurance. The decision tree was constructed to evaluate costs and effectiveness of different strategies used for treatment of non-pregnant, adult women. As a positive outcome of the treatment number of cases where simptoms disapered is used. The results implied that the least costly strategy available is empiric treatment. More expensive but with greater outcomes was the strategy involving laboratory test together with empiric treatment. Although the empiric treatment proved to be cost-effective and in accordance with current recommendations and guidelines for therapy, recognition of the impact of this strategy upon antibiotic resistance may lead to conclusion that the dipstick strategy is superior strategy., Infekcije urinarnog trakta zahvataju donje i gornje delove urinarnog trakta. Terapija infekcija se razlikuje u zavisnosti da li su u pitanju komplikovane ili nekomplikovane infekcije kao i od mesta infekcije. Cilj ovog rada je farmakoekonomska analiza isplativosti primene različitih strategija u lečenju infekcija urinarnog trakta iz perspektive Republičkog fonda za zdravstveno osiguranje. Zarad procene troškova i efikasnosti primene različitih strategija u lečenju infekcija urinarnog trakta u odraslih žena koje nisu trudne konstruisano je drvo odlučivanja. Kao ishod lečenja posmatran je broj slučajeva u kojima je došlo do prestanka simptoma. Rezultati istraživanja su pokazali da je najisplativija strategija empirijska primena antibiotika. Nešto skuplja i efikasnija strategija je primena laboratorijskih testova uz empirijsku primenu antibiotika. Iako je empirijska primena antibiotika troškovno isplativa i u skladu sa važećim preporukama i protokolima lečenja infekcije urinarnog trakta, ukoliko se razmotri i antibiotska rezistencija kao rastući zdravstveni problem, strategija primene dipstik testa može biti superiorna.",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "Antibacterial therapy of the urinary tract infections: Pharmacoeconomic aspect, Upotreba antibakterijskih lekova u lečenju infekcija urinarnog trakta - farmakoekonomski aspect",
volume = "65",
number = "1",
pages = "47-57",
doi = "10.5937/arhfarm1501047L"
}

Lakić, D., Tadić, I., Odalović, M.,& Kolundžić, S.. (2015). Antibacterial therapy of the urinary tract infections: Pharmacoeconomic aspect. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 65(1), 47-57.
https://doi.org/10.5937/arhfarm1501047L

Lakić D, Tadić I, Odalović M, Kolundžić S. Antibacterial therapy of the urinary tract infections: Pharmacoeconomic aspect. in Arhiv za farmaciju. 2015;65(1):47-57.
doi:10.5937/arhfarm1501047L .

Lakić, Dragana, Tadić, Ivana, Odalović, Marina, Kolundžić, Svetlana, "Antibacterial therapy of the urinary tract infections: Pharmacoeconomic aspect" in Arhiv za farmaciju, 65, no. 1 (2015):47-57,
https://doi.org/10.5937/arhfarm1501047L . .

TY  - CONF
AU  - Bogavac-Stanojević, Nataša
AU  - Petrović, S.
AU  - Lakić, Dragana
AU  - Antić, Peco A.
AU  - Vulicević, Irena
AU  - Ivanišević, Ivana
AU  - Kotur-Stevuljević, Jelena
AU  - Jelić-Ivanović, Zorana
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2111
AB  - Objectives: Children undergoing cardiac surgery for congenital heart disease are
more likely to experience development of acute kidney injury (AKI) in the immedi-
ate postoperative period. In current clinical practice, AKI diagnosis is based on a
rise in serum creatinine (sCr) levels, which occurs 2-3 days after the initiating renal
insult. Many new biomarkers offer promise for earlier AKI diagnosis. The objective was to assess the incremental cost effectiveness of using serum CysC (sCysC), urine
NGAL (uNGAL) and urine L-FABP (uL-FABP) for the diagnosis of AKI in children
after cardiac surgery compared with current diagnostic method (monitoring of sCr
level). MeThoDs: We developed a decision analytical model to estimate quality-
adjusted life years (QALY), lifetime costs and incremental cost-effectiveness of dif-
ferent biomarker-based diagnostic strategies which can be used in clinical practice
compared to current strategy.This model simulates detection of AKI, its progression
to chronic kidney disease (CKD) and CKD treatment in cohort of patients younger
than 18 years. ResulTs: The cost-effectiveness ratios were between $1485/QALY for
sCr and $3579/QALY for uNGAL. uNGAL and sCys C strategies yielded higher costs
and lower effectiveness (ie. dominated) compared to uL-FABP strategy. uL-FABP
added 1.43 QALY compared to current diagnostic method at an additional cost of
$8521.87. ICER for uL-FABP compared to sCr was $5959.35/QALY. Probabilistic sensi-
tivity analyses indicated that the uL-FABP strategy was cost-effective for all 10.000
patient simulations at specified $50000/QALY threshold. ConClusions: Our results
suggest that the use of uL-FABP is likely to represent an economically advantageous
strategy for early AKI diagnosis in children after cardiac surgery. However, we need
rapid screening uL-FABP test to ensure timely and efficient AKI treatment.
PB  - Elsevier Science Inc
C3  - Value in Health
T1  - Cost-effectiveness analysis of the new biomarkers for diagnosis of acute kidney injury in children after cardiac surgery
VL  - 17
IS  - 7
IS  - 7
SP  - A510
EP  - A511
DO  - 10.1016/j.jval.2014.08.1567
ER  - 

@conference{
author = "Bogavac-Stanojević, Nataša and Petrović, S. and Lakić, Dragana and Antić, Peco A. and Vulicević, Irena and Ivanišević, Ivana and Kotur-Stevuljević, Jelena and Jelić-Ivanović, Zorana",
year = "2014",
abstract = "Objectives: Children undergoing cardiac surgery for congenital heart disease are
more likely to experience development of acute kidney injury (AKI) in the immedi-
ate postoperative period. In current clinical practice, AKI diagnosis is based on a
rise in serum creatinine (sCr) levels, which occurs 2-3 days after the initiating renal
insult. Many new biomarkers offer promise for earlier AKI diagnosis. The objective was to assess the incremental cost effectiveness of using serum CysC (sCysC), urine
NGAL (uNGAL) and urine L-FABP (uL-FABP) for the diagnosis of AKI in children
after cardiac surgery compared with current diagnostic method (monitoring of sCr
level). MeThoDs: We developed a decision analytical model to estimate quality-
adjusted life years (QALY), lifetime costs and incremental cost-effectiveness of dif-
ferent biomarker-based diagnostic strategies which can be used in clinical practice
compared to current strategy.This model simulates detection of AKI, its progression
to chronic kidney disease (CKD) and CKD treatment in cohort of patients younger
than 18 years. ResulTs: The cost-effectiveness ratios were between $1485/QALY for
sCr and $3579/QALY for uNGAL. uNGAL and sCys C strategies yielded higher costs
and lower effectiveness (ie. dominated) compared to uL-FABP strategy. uL-FABP
added 1.43 QALY compared to current diagnostic method at an additional cost of
$8521.87. ICER for uL-FABP compared to sCr was $5959.35/QALY. Probabilistic sensi-
tivity analyses indicated that the uL-FABP strategy was cost-effective for all 10.000
patient simulations at specified $50000/QALY threshold. ConClusions: Our results
suggest that the use of uL-FABP is likely to represent an economically advantageous
strategy for early AKI diagnosis in children after cardiac surgery. However, we need
rapid screening uL-FABP test to ensure timely and efficient AKI treatment.",
publisher = "Elsevier Science Inc",
journal = "Value in Health",
title = "Cost-effectiveness analysis of the new biomarkers for diagnosis of acute kidney injury in children after cardiac surgery",
volume = "17",
number = "7, 7",
pages = "A510-A511",
doi = "10.1016/j.jval.2014.08.1567"
}

Bogavac-Stanojević, N., Petrović, S., Lakić, D., Antić, P. A., Vulicević, I., Ivanišević, I., Kotur-Stevuljević, J.,& Jelić-Ivanović, Z.. (2014). Cost-effectiveness analysis of the new biomarkers for diagnosis of acute kidney injury in children after cardiac surgery. in Value in Health
Elsevier Science Inc., 17(7), A510-A511.
https://doi.org/10.1016/j.jval.2014.08.1567

Bogavac-Stanojević N, Petrović S, Lakić D, Antić PA, Vulicević I, Ivanišević I, Kotur-Stevuljević J, Jelić-Ivanović Z. Cost-effectiveness analysis of the new biomarkers for diagnosis of acute kidney injury in children after cardiac surgery. in Value in Health. 2014;17(7):A510-A511.
doi:10.1016/j.jval.2014.08.1567 .

Bogavac-Stanojević, Nataša, Petrović, S., Lakić, Dragana, Antić, Peco A., Vulicević, Irena, Ivanišević, Ivana, Kotur-Stevuljević, Jelena, Jelić-Ivanović, Zorana, "Cost-effectiveness analysis of the new biomarkers for diagnosis of acute kidney injury in children after cardiac surgery" in Value in Health, 17, no. 7 (2014):A510-A511,
https://doi.org/10.1016/j.jval.2014.08.1567 . .

TY  - JOUR
AU  - Lakić, Dragana
AU  - Tadić, Ivana
AU  - Odalović, Marina
AU  - Tasić, Ljiljana
AU  - Sabo, Ana
AU  - Mećava, Aleksandra
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2244
AB  - Introduction. Respiratory infections are the most common infections in children. The aims of the study were to analyze the use of antibiotics for respiratory infections in the period 2008 - 2010 in children's population in region of Niš and to estimate the rational use of antibiotics in relation to the recommendations of the National Guidelines for physicians in primary care. Material and methods. Data source was a Pharmacy Niš database. Antibiotics prescriptions were selected for the following diagnoses: H65-H75 (acute otitis media, mastoiditis), J01 (acute sinusitis), J02-J03 (tonsillopharyngitis), J12-J18 (community acquired pneumonia), J20 (acute bronchitis), J32 (chronic sinusitis), J42 (chronic bronchitis). Antibiotic consumption was expressed in defined daily dose/1000 inhabitants/day. Results. The most widely prescribed antibiotic for the treatment of upper respiratory tract infections in children during the three years was amoxicillin (34.63; 32.50 and 31.00 defined daily dose/1000 inhabitants/day in 2008, 2009 and 2010, respectively). In the treatment of infections of the middle ear and mastoid, the combination of amoxicillin and clavulanic acid, was the most prescribed antibiotics (60% of total consumption of antibiotics for this indication). Azithromycin was the most widely prescribed antibiotic for the treatment of lower respiratory tract infections in children during the observed period (6.92; 8.20 and 7.18 defined daily dose/1000 inhabitans/day in 2008, 2009 and 2010, respectively). Conclusion. Recommendations of national guidelines are not complied with the treatment of upper and lower respiratory infections in the children population in region of Niš. This could be a sign of potentially irrational use of antibiotics that need to be further examined. Education of physicians can influence irrational use of antibiotics.
AB  - Uvod. Infekcije respiratornog sistema predstavljaju najčešće infekcije kod dece. Ciljevi ovog rada jesu analiza potrošnje antibiotika u lečenju infekcija gornjih i donjih respiratornih puteva kod dece u Nišavskom okrugu i procena racionalnosti upotrebe antibiotika u odnosu na preporuke Nacionalnog vodiča za lekare u primarnoj zdravstvenoj zaštiti. Materijal i metode. Kao izvor podataka korišćena je baza podataka Apoteke Niš za period 2008-2010. godine. Selektovani su svi izdati recepti antibiotika propisani deci starosti 0-19 godina za terapiju infekcija respiratornog trakta uključujući infekcije srednjeg uva ((H65-H75 (akutni otitis media i mastoiditis), J01 (akutni sinuzitis), J02-J03 (tonzilofaringitis), J32 (hronični sinuzitis) (J12-J18 (blaga do umerena pneumonija izazvana vanbolničkim uzročnikom), J20 (akutni bronhitis), J42 (hronični bronhitis)). Potrošnja je izražena u definitivnoj dnevnoj dozi/1 000 stanovnika/dan. Rezultati. Najpropisivaniji antibiotik za terapiju infekcija gornjeg respiratornog trakta kod dece u posmatranom periodu bio je amoksicilin (34,63; 32,5 i 31 definitivnoj dnevnoj dozi/1 000 stanovnika/ dan tokom 2008, 2009. i 2010. godine). Za terapiju infekcije srednjeg uva i mastoidnog nastavka najčešće je korišćena kombinacija amoksicilina i klavulanske kiseline (60% ukupne potrošnje svih antibiotika za ovu indikaciju). Azitromicin je bio najpropisivaniji antibiotik za terapiju infekcija donjeg respiratornog trakta kod dece tokom posmatranog perioda (6,92; 8,2 i 7,18 definitivnoj dnevnoj dozi/1 000 stanovnika/dan tokom 2008, 2009. i 2010. godine). Zaključak. Preporuke nacionalnih vodiča nisu poštovane ni u slučaju terapije gornjih ni donjih respiratornih infekcija kod dece u Nišavskom regionu. To može biti znak potencijalno neracionalne upotrebe antibiotika koju je potrebno dodatno istražiti. Dodatna edukacija lekara mogla bi uticati na smanjivanje neracionalne upotrebe antibiotika.
PB  - Društvo lekara Vojvodine Srpskog lekarskog društva, Novi Sad
T2  - Medicinski pregled
T1  - Analysis of antibiotic consumption for treating respiratory tract infections in children and compliance with the national clinical guidelines
T1  - Analiza potrošnje antibiotika za lečenje infekcija respiratornog trakta u dečjoj populaciji i usklađenosti sa nacionalnim vodičima dobre kliničke prakse
VL  - 67
IS  - 9-10
SP  - 282
EP  - 289
DO  - 10.2298/MPNS1410282L
ER  - 

@article{
author = "Lakić, Dragana and Tadić, Ivana and Odalović, Marina and Tasić, Ljiljana and Sabo, Ana and Mećava, Aleksandra",
year = "2014",
abstract = "Introduction. Respiratory infections are the most common infections in children. The aims of the study were to analyze the use of antibiotics for respiratory infections in the period 2008 - 2010 in children's population in region of Niš and to estimate the rational use of antibiotics in relation to the recommendations of the National Guidelines for physicians in primary care. Material and methods. Data source was a Pharmacy Niš database. Antibiotics prescriptions were selected for the following diagnoses: H65-H75 (acute otitis media, mastoiditis), J01 (acute sinusitis), J02-J03 (tonsillopharyngitis), J12-J18 (community acquired pneumonia), J20 (acute bronchitis), J32 (chronic sinusitis), J42 (chronic bronchitis). Antibiotic consumption was expressed in defined daily dose/1000 inhabitants/day. Results. The most widely prescribed antibiotic for the treatment of upper respiratory tract infections in children during the three years was amoxicillin (34.63; 32.50 and 31.00 defined daily dose/1000 inhabitants/day in 2008, 2009 and 2010, respectively). In the treatment of infections of the middle ear and mastoid, the combination of amoxicillin and clavulanic acid, was the most prescribed antibiotics (60% of total consumption of antibiotics for this indication). Azithromycin was the most widely prescribed antibiotic for the treatment of lower respiratory tract infections in children during the observed period (6.92; 8.20 and 7.18 defined daily dose/1000 inhabitans/day in 2008, 2009 and 2010, respectively). Conclusion. Recommendations of national guidelines are not complied with the treatment of upper and lower respiratory infections in the children population in region of Niš. This could be a sign of potentially irrational use of antibiotics that need to be further examined. Education of physicians can influence irrational use of antibiotics., Uvod. Infekcije respiratornog sistema predstavljaju najčešće infekcije kod dece. Ciljevi ovog rada jesu analiza potrošnje antibiotika u lečenju infekcija gornjih i donjih respiratornih puteva kod dece u Nišavskom okrugu i procena racionalnosti upotrebe antibiotika u odnosu na preporuke Nacionalnog vodiča za lekare u primarnoj zdravstvenoj zaštiti. Materijal i metode. Kao izvor podataka korišćena je baza podataka Apoteke Niš za period 2008-2010. godine. Selektovani su svi izdati recepti antibiotika propisani deci starosti 0-19 godina za terapiju infekcija respiratornog trakta uključujući infekcije srednjeg uva ((H65-H75 (akutni otitis media i mastoiditis), J01 (akutni sinuzitis), J02-J03 (tonzilofaringitis), J32 (hronični sinuzitis) (J12-J18 (blaga do umerena pneumonija izazvana vanbolničkim uzročnikom), J20 (akutni bronhitis), J42 (hronični bronhitis)). Potrošnja je izražena u definitivnoj dnevnoj dozi/1 000 stanovnika/dan. Rezultati. Najpropisivaniji antibiotik za terapiju infekcija gornjeg respiratornog trakta kod dece u posmatranom periodu bio je amoksicilin (34,63; 32,5 i 31 definitivnoj dnevnoj dozi/1 000 stanovnika/ dan tokom 2008, 2009. i 2010. godine). Za terapiju infekcije srednjeg uva i mastoidnog nastavka najčešće je korišćena kombinacija amoksicilina i klavulanske kiseline (60% ukupne potrošnje svih antibiotika za ovu indikaciju). Azitromicin je bio najpropisivaniji antibiotik za terapiju infekcija donjeg respiratornog trakta kod dece tokom posmatranog perioda (6,92; 8,2 i 7,18 definitivnoj dnevnoj dozi/1 000 stanovnika/dan tokom 2008, 2009. i 2010. godine). Zaključak. Preporuke nacionalnih vodiča nisu poštovane ni u slučaju terapije gornjih ni donjih respiratornih infekcija kod dece u Nišavskom regionu. To može biti znak potencijalno neracionalne upotrebe antibiotika koju je potrebno dodatno istražiti. Dodatna edukacija lekara mogla bi uticati na smanjivanje neracionalne upotrebe antibiotika.",
publisher = "Društvo lekara Vojvodine Srpskog lekarskog društva, Novi Sad",
journal = "Medicinski pregled",
title = "Analysis of antibiotic consumption for treating respiratory tract infections in children and compliance with the national clinical guidelines, Analiza potrošnje antibiotika za lečenje infekcija respiratornog trakta u dečjoj populaciji i usklađenosti sa nacionalnim vodičima dobre kliničke prakse",
volume = "67",
number = "9-10",
pages = "282-289",
doi = "10.2298/MPNS1410282L"
}

Lakić, D., Tadić, I., Odalović, M., Tasić, L., Sabo, A.,& Mećava, A.. (2014). Analysis of antibiotic consumption for treating respiratory tract infections in children and compliance with the national clinical guidelines. in Medicinski pregled
Društvo lekara Vojvodine Srpskog lekarskog društva, Novi Sad., 67(9-10), 282-289.
https://doi.org/10.2298/MPNS1410282L

Lakić D, Tadić I, Odalović M, Tasić L, Sabo A, Mećava A. Analysis of antibiotic consumption for treating respiratory tract infections in children and compliance with the national clinical guidelines. in Medicinski pregled. 2014;67(9-10):282-289.
doi:10.2298/MPNS1410282L .

Lakić, Dragana, Tadić, Ivana, Odalović, Marina, Tasić, Ljiljana, Sabo, Ana, Mećava, Aleksandra, "Analysis of antibiotic consumption for treating respiratory tract infections in children and compliance with the national clinical guidelines" in Medicinski pregled, 67, no. 9-10 (2014):282-289,
https://doi.org/10.2298/MPNS1410282L . .

TY  - CONF
AU  - Lakić, Dragana
AU  - Tadić, Ivana
AU  - Odalović, Marina
AU  - Petrović, B.
AU  - Petrova, Guenka
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2110
AB  - Oobjectives: To assess cost, clinical outcomes and cost-effectiveness of different
types of labor in singleton pregnancies. Methods: A decision model was used
to compare vaginal labor, induced labor and planned cesarean section. All data
were taken from the Book of Labor from the University Hospital for Gynecology
and Obstetrics “Narodni Front” in Serbia, for labors conducted during one month
period in 2011. Successful delivery, (i. e. labor that began up to 42 gestation weeks,
without maternal mortality and the newborn Apgar scores greater than or equal
to seven in the first and fifth minute of life) was considered as the outcome of the
cost effectiveness analysis. To test the robustness of this definition probabilistic
sensitivity analysis was performed. Results: From a total of 667 births, vaginal
labor was conducted in 98 cases, induced vaginal in 442, while planned caesarean
section was performed 127 times. Emergency caesarean section as a complication
was much higher in the vaginal labor cohort compared to the induced vaginal
cohort (OR = 17.374, 95% CI: 8.522 to 35.418, p < 0.001). The least costly type of labor
was induced vaginal labor: average cost 461 euro, with an effectiveness of 98.17%.
Both, vaginal and planned cesarean labor, were dominated by the induced labor.
The results were robust. ConClusions: Elective induction of labor was associated
with the lowest cost compared to other types of labor, with favorable maternal and
neonatal outcomes.
PB  - Elsevier Inc.
C3  - Value in Health
T1  - A cost-effectiveness analysis of different types of labor for singleton pregnancy - real life data
VL  - 17
IS  - 7
SP  - A509
EP  - A509
DO  - 10.1016/j.jval.2014.08.1557
ER  - 

@conference{
author = "Lakić, Dragana and Tadić, Ivana and Odalović, Marina and Petrović, B. and Petrova, Guenka",
year = "2014",
abstract = "Oobjectives: To assess cost, clinical outcomes and cost-effectiveness of different
types of labor in singleton pregnancies. Methods: A decision model was used
to compare vaginal labor, induced labor and planned cesarean section. All data
were taken from the Book of Labor from the University Hospital for Gynecology
and Obstetrics “Narodni Front” in Serbia, for labors conducted during one month
period in 2011. Successful delivery, (i. e. labor that began up to 42 gestation weeks,
without maternal mortality and the newborn Apgar scores greater than or equal
to seven in the first and fifth minute of life) was considered as the outcome of the
cost effectiveness analysis. To test the robustness of this definition probabilistic
sensitivity analysis was performed. Results: From a total of 667 births, vaginal
labor was conducted in 98 cases, induced vaginal in 442, while planned caesarean
section was performed 127 times. Emergency caesarean section as a complication
was much higher in the vaginal labor cohort compared to the induced vaginal
cohort (OR = 17.374, 95% CI: 8.522 to 35.418, p < 0.001). The least costly type of labor
was induced vaginal labor: average cost 461 euro, with an effectiveness of 98.17%.
Both, vaginal and planned cesarean labor, were dominated by the induced labor.
The results were robust. ConClusions: Elective induction of labor was associated
with the lowest cost compared to other types of labor, with favorable maternal and
neonatal outcomes.",
publisher = "Elsevier Inc.",
journal = "Value in Health",
title = "A cost-effectiveness analysis of different types of labor for singleton pregnancy - real life data",
volume = "17",
number = "7",
pages = "A509-A509",
doi = "10.1016/j.jval.2014.08.1557"
}

Lakić, D., Tadić, I., Odalović, M., Petrović, B.,& Petrova, G.. (2014). A cost-effectiveness analysis of different types of labor for singleton pregnancy - real life data. in Value in Health
Elsevier Inc.., 17(7), A509-A509.
https://doi.org/10.1016/j.jval.2014.08.1557

Lakić D, Tadić I, Odalović M, Petrović B, Petrova G. A cost-effectiveness analysis of different types of labor for singleton pregnancy - real life data. in Value in Health. 2014;17(7):A509-A509.
doi:10.1016/j.jval.2014.08.1557 .

Lakić, Dragana, Tadić, Ivana, Odalović, Marina, Petrović, B., Petrova, Guenka, "A cost-effectiveness analysis of different types of labor for singleton pregnancy - real life data" in Value in Health, 17, no. 7 (2014):A509-A509,
https://doi.org/10.1016/j.jval.2014.08.1557 . .

TY  - JOUR
AU  - Lakić, Dragana
AU  - Tasić, Ljiljana
AU  - Kos, Mitja
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2264
AB  - Background/Aim. Cardiovascular disease imposes a burden to society in terms of mortality, morbidity and economic losses. The aim of this study was to estimate the economic burden of cardiovascular disease in Serbia in 2009 from the perspective of the society. Methods. For the purpose of the study cardiovascular disease was defined by the International Classification of Diseases, 10th revision, as the following diagnosis: hypertension, coronary heart disease, cardiomyopathy, heart failure and cerebrovascular disease. The prevalence, top-down method was used to quantify the annual cardiovascular costs. Productivity losses were estimated using the human capital approach and the friction cost method. A discount rate of 5% was used to convert all future lifetime earnings into the present value. Results. The total direct costs of cardiovascular disease in 2009 were € 400 million. The results showed that more than half a million working days were lost due to incapacity resulting from cardiovascular diseases, yielding the € 113.9 million. The majority of total costs (€ 514.3 million) were for: medication (29.94%), hospital days (28.97%) and hospital inpatient care - surgical and diagnostic interventions (17.84%). The results were robust to a change in 20% of volume or the unit price of all direct and indirect cost and to discount rate 2% and 10%. Conclusions. The total cardiovascular disease costs in 2009 represented approximately 1.8% of the Serbian gross domestic product. The results of the study would be valuable to health policy makers to bridge the gap between invested resources and needs, in order to improve cardiovascular disease outcomes.
AB  - Uvod/Cilj. Kardiovaskularne bolesti predstavljaju teret za društvo u smislu mortaliteta, morbiditeta i ekonomskih gubitaka. Cilj ove studije bio je procena ekonomskog značaja kardiovaskularnih bolesti u Srbiji u 2009. godini iz perspektive društva. Metode. Za potrebe istraživanja, kardiovaskularne bolesti su definisane pomoću Međunarodne klasifikacije bolesti, 10. revizija, kao sledeće dijagnoze: hipertenzija, koronarne bolesti, kardiomiopatija, srčana insuficijencija i cerebrovaskularne bolesti. Korišćen je top-down metod, baziran na prevalenciji, kako bi se kvantifikovali godišnji kardiovaskularni troškovi. Troškovi smanjene produktivnosti su procenjeni korišćenjem dva pristupa: pristup ljudskom kapitalu (human capital approach) i metod frikcionih troškova (friction cost method). Za obračunavanje troškova u sadašnju vrednost korišćena je diskontna stopa od 5%. Rezultati. Ukupni direktni troškovi kardiovaskularnih bolesti u 2009. godini iznosili su 400 miliona evra. Rezultati pokazuju da je više od pola miliona radnih dana izgubljeno zbog nesposobnosti usled kardiovaskularnih bolesti, dajući ukupno 113,9 miliona evra indirektne troškove. Većina ukupnih troškova (514,3 miliona evra) bili su za: lekove (29,94%), hospitalizaciju (28,97%) i bolničko lečenje - hirurške intervencije i dijagnostiku (17,84%). Rezultati su bili robusni na promene od 20% u volumenu ili ceni pojedinih kategorija troškova, kao i na primenjenu diskontnu stopu od 2% i od 10%. Zaključak. Ukupni troškovi kardiovaskularnih bolesti u 2009. godini su predstavljali oko 1,8% bruto domaćeg proizvoda. Rezultati studije su značajni za kreiranje zdravstvene politike i premošćavanja jaza između uloženih sredstava i potreba, a u cilju poboljšanja ishoda kardiovaskularnih bolesti.
PB  - Vojnomedicinska akademija - Institut za naučne informacije, Beograd
T2  - Vojnosanitetski pregled
T1  - Economic burden of cardiovascular diseases in Serbia
T1  - Kardiovaskularne bolesti u Srbiji - ekonomski teret
VL  - 71
IS  - 2
SP  - 137
EP  - 143
DO  - 10.2298/VSP1402137L
ER  - 

@article{
author = "Lakić, Dragana and Tasić, Ljiljana and Kos, Mitja",
year = "2014",
abstract = "Background/Aim. Cardiovascular disease imposes a burden to society in terms of mortality, morbidity and economic losses. The aim of this study was to estimate the economic burden of cardiovascular disease in Serbia in 2009 from the perspective of the society. Methods. For the purpose of the study cardiovascular disease was defined by the International Classification of Diseases, 10th revision, as the following diagnosis: hypertension, coronary heart disease, cardiomyopathy, heart failure and cerebrovascular disease. The prevalence, top-down method was used to quantify the annual cardiovascular costs. Productivity losses were estimated using the human capital approach and the friction cost method. A discount rate of 5% was used to convert all future lifetime earnings into the present value. Results. The total direct costs of cardiovascular disease in 2009 were € 400 million. The results showed that more than half a million working days were lost due to incapacity resulting from cardiovascular diseases, yielding the € 113.9 million. The majority of total costs (€ 514.3 million) were for: medication (29.94%), hospital days (28.97%) and hospital inpatient care - surgical and diagnostic interventions (17.84%). The results were robust to a change in 20% of volume or the unit price of all direct and indirect cost and to discount rate 2% and 10%. Conclusions. The total cardiovascular disease costs in 2009 represented approximately 1.8% of the Serbian gross domestic product. The results of the study would be valuable to health policy makers to bridge the gap between invested resources and needs, in order to improve cardiovascular disease outcomes., Uvod/Cilj. Kardiovaskularne bolesti predstavljaju teret za društvo u smislu mortaliteta, morbiditeta i ekonomskih gubitaka. Cilj ove studije bio je procena ekonomskog značaja kardiovaskularnih bolesti u Srbiji u 2009. godini iz perspektive društva. Metode. Za potrebe istraživanja, kardiovaskularne bolesti su definisane pomoću Međunarodne klasifikacije bolesti, 10. revizija, kao sledeće dijagnoze: hipertenzija, koronarne bolesti, kardiomiopatija, srčana insuficijencija i cerebrovaskularne bolesti. Korišćen je top-down metod, baziran na prevalenciji, kako bi se kvantifikovali godišnji kardiovaskularni troškovi. Troškovi smanjene produktivnosti su procenjeni korišćenjem dva pristupa: pristup ljudskom kapitalu (human capital approach) i metod frikcionih troškova (friction cost method). Za obračunavanje troškova u sadašnju vrednost korišćena je diskontna stopa od 5%. Rezultati. Ukupni direktni troškovi kardiovaskularnih bolesti u 2009. godini iznosili su 400 miliona evra. Rezultati pokazuju da je više od pola miliona radnih dana izgubljeno zbog nesposobnosti usled kardiovaskularnih bolesti, dajući ukupno 113,9 miliona evra indirektne troškove. Većina ukupnih troškova (514,3 miliona evra) bili su za: lekove (29,94%), hospitalizaciju (28,97%) i bolničko lečenje - hirurške intervencije i dijagnostiku (17,84%). Rezultati su bili robusni na promene od 20% u volumenu ili ceni pojedinih kategorija troškova, kao i na primenjenu diskontnu stopu od 2% i od 10%. Zaključak. Ukupni troškovi kardiovaskularnih bolesti u 2009. godini su predstavljali oko 1,8% bruto domaćeg proizvoda. Rezultati studije su značajni za kreiranje zdravstvene politike i premošćavanja jaza između uloženih sredstava i potreba, a u cilju poboljšanja ishoda kardiovaskularnih bolesti.",
publisher = "Vojnomedicinska akademija - Institut za naučne informacije, Beograd",
journal = "Vojnosanitetski pregled",
title = "Economic burden of cardiovascular diseases in Serbia, Kardiovaskularne bolesti u Srbiji - ekonomski teret",
volume = "71",
number = "2",
pages = "137-143",
doi = "10.2298/VSP1402137L"
}

Lakić, D., Tasić, L.,& Kos, M.. (2014). Economic burden of cardiovascular diseases in Serbia. in Vojnosanitetski pregled
Vojnomedicinska akademija - Institut za naučne informacije, Beograd., 71(2), 137-143.
https://doi.org/10.2298/VSP1402137L

Lakić D, Tasić L, Kos M. Economic burden of cardiovascular diseases in Serbia. in Vojnosanitetski pregled. 2014;71(2):137-143.
doi:10.2298/VSP1402137L .

Lakić, Dragana, Tasić, Ljiljana, Kos, Mitja, "Economic burden of cardiovascular diseases in Serbia" in Vojnosanitetski pregled, 71, no. 2 (2014):137-143,
https://doi.org/10.2298/VSP1402137L . .